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Abstract of the thesis entitled: 
A Study of Drug Resistance Mechanism in Human Carcinoma Cells after 
Hypoxia Exposure 
Submitted by CHOI Siu Cheong 
for the degree of Master of Philosophy in Biochemistry 
at the Chinese University of Hong Kong in July 2008 
Hypoxia is a common phenomenon observed in solid tumors and is mainly due to the 
improper development of vasculature. It was reported that hypoxia conferred 
resistance to cancer therapy, especially for chemotherapy and radiotherapy. However, 
there is not much work focused on the drug resistance in hypoxia/reoxygenation 
treated carcinoma cells. In the present study, the drug resistance mechanism in 
human carcinoma cells, HepG2 and A431, after hypoxia/reoxygenation treatment 
(GIOHR, G20HR and AlOHR and A20HR) were investigated. 
The sensitivity in HepG2 and A431 cells to 13 drugs was examined and it was 
observed that hypoxia/reoxygenation treated cells were generally resistant to the 
selected drugs. Among them, the resistance mechanisms for cisplatin and 
doxorubicin were further studied in HepG2 and A431 cells respectively. Accordingly, 
the overexpression of P-glycoprotein in AlOHR and A20HR cells was found to be 
related to the resistance to doxorubicin treatment. In addition, the expression of P-
glycoprotein was suspected to be regulated by DNA methylation in the promoter 
region of mdrl gene. 
For the resistance mechanism to cisplatin in GIOHR and G20HR cells, mismatch 
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repair gene PMS2 seemed to play an important role. The down-regulation of PMS2 
was correlated with the cisplatin resistance. Also, our results showed that the 
expression of PMS2 may be regulated by both DNA methylation and histone 
deacetylation. Besides, reduced expressions of pro-apoptotic proteins and enhanced 
expressions of anti-apoptotic proteins were observed in GIOHR and G20HR cells 
and this phenomenon also seemed to contribute for the reduction of cisplatin-induced 
apoptosis. Furthermore, PMS2 was found to act as a direct signaling molecule in 
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Although many kinds of treatment approaches have been developed and 
administered in the therapy of cancer, the therapy is still not promising as none can 
have a 100% cure of cancer. Instead, development of resistance to the therapy often 
exists clinically, particularly for the advanced cancer. In fact, cellular heterogeneity, 
redundancy of molecular pathways and continuous changing in microenvironment 
may contribute to the survival, motility and metastasis of solid tumors. Moreover, the 
proliferation and progression of the tumor are likely dependent on more than one 
abnormally activated signaling pathway. Therefore, treatments interfering only a 
single target seem becoming less and less effective. In contrast, combined therapy is 
thought to be an attractive therapeutic strategy. 
1.1.1 Treatment resistance in cancer 
Treatment resistance in cancer can be intrinsic or acquired after therapy. 
Intrinsic resistance may be related to the epigenetic regulation of the cell physiology. 
For the acquired resistance, it may be contributed by the expressions of energy-
dependent transporters, development of defect in drug-induced apoptosis, abnormal 
detoxification of drugs, enhanced DNA repair and cell cycle arrest. For instance, 
multidrug resistance-associated protein 4 (MRP4) ejected topotecan and conferred 
the resistance [Tian et.al, 2006]; Polymorphism in the codon 72 of p53 was 
associated with shorter time of progression and overall survival in patients with 
metastatic breast cancer [Vannini et.al, 2008]; Multidrug resistance has been linked 
to sphingolipid metabolism by glucosylceramide synthase (GCS) in breast cancer 
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[Ruckhaberle et.al., 2008]; Enhanced nucleotide excision repair (NER) capacity led 
to cisplatin resistance [Wu et.al., 2003]; glucocorticoids induced therapeutic 
resistance in malignant solid tumors by decreasing their proliferation rates [Mattem 
et.al, 2007]. 
1.1.1.1 Surgery 
Surgery is the most traditional clinical method to cure cancer by physically 
removal of the cancerous tissue. Although surgery alone usually cannot remove 
cancerous tissue completely and recurrence usually can happen, there are several 
benefits of surgery. First of all, it can eliminate the poorly vascularised tumor that is 
usually drug-resistant and malignant. In addition, it improves the perfusion in the 
small residual tumor mass that favors the function of chemotherapy. Furthermore, the 
host immunocompetence is enhanced. To achieve the optimal level of surgery 
treatment, there are different definitions for different cancers. For ovarian cancer, it 
refers to the complete debulking to no visible tumor residuals [du Bois and Harter, 
2006]. Since surgery alone is not an effective method of treating cancer, it usually 
combines with other types of treatment such as chemotherapy or radiotherapy to 
achieve a better outcome. In a case study, a combination of surgery and adjuvant 
chemotherapy results in a complete and long-lasting remission of an aggressive 




Chemotherapy refers to the use of drugs to kill cancerous cells. Mainly, it 
works by stopping cell proliferation or initiating cell death by damaging DNA 
directly or indirectly. In most cases, drugs were applied clinically without knowing 
their exact action mechanisms. Chemotherapeutic drugs can be categorized 
according to their function and origin. They include alkylating agents, which act by 
adding alkyl groups, antimetabolites, which interfere cell division, plant alkaloids, 
which disrupt microtubule function, topoisomerase inhibitors, which affect the 
transcription and replication of DNA. The major obstacle of chemotherapy is 
resistance and tremendous reports revealed the appearance of chemotherapeutic 
resistance in clinical cases. For example, clinical resistance to platinum-based 
chemotherapy in small cell lung cancer was related to the expression of MRP2 
[Ushijima et.al., 2007], copper-transportin P-type ATPase contributed resistance to 
camptothecin in clinical colon cancer [Owatari et.al, 2007], enhanced nuclear 
metallothionein expression led to poor clinical outcome of cisplatin treatment in 
ovarian cancer [Surowiak et.al., 2007]. Undoubtedly, the clinical resistance was 
unlimited to particular cancer and contributed by multiple reasons. 
1.1.1.3 Radiotherapy 
Apart from surgery and chemotherapy, radiotherapy is also one of the most 
common types of treatment for cancer. It makes use of the ionizing radiation to kill 
and control the growth of cancerous tissues. It can either be used for curative or 
adjuvant cancer treatment. The action mechanism of radiotherapy is simple and clear. 
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It works by damaging the DNA of cancer cells by photon, electron proton, neutron or 
ion beam. The effectiveness of radiotherapy depends on the availability of free 
oxygen in the cells. Hence, this therapy is usually failure in treating hypoxic solid 
tumors. Nowadays, radiation therapy has become a safer and more successful therapy 
due to the rapid development in imaging technique. More accurate treatment can be 
achieved by calculating the dose distributions, controlling the accelerator and 
multileaf collimator and checking patient set-up [Svensson et.al., 2003]. Nonetheless, 
development of resistance to radiotherapy was frequently observed. Generally, the 
resistance mechanism was related to the alteration in cell cycle and apoptotic 
pathways. Regarding the cell cycle, cells at G2 or M phase are more sensitive to 
radiation. It was found that overexpression of cyclin B1 was associated with 
resistance to radiotherapy [Hassan et.al., 2002]. For the apoptotic pathways, Imoto I 
suggested that the overexpression of cIAPl was correlated with radiotherapeutic 
resistance in cervical cancer [Imoto et.al.’ 2002]. Recently, the glucose metabolism 
was found to affect the effectiveness of radiotherapy in squamous cell carcinoma of 
the oral cavity [Kunkel et.al, 2007]. 
1.1.1.4 Hormonal therapy 
Hormonal therapy was restricted to limited types of cancers with hormonally 
responsive tissues such as breast cancer and prostate cancer. The principle of this 
therapy is the manipulation of the endocrine system by the administration of 
hormones or interference with the function of hormone. Rarely, hormonal therapy is 
used solely to cure cancer. Instead, it is used as a supplement for other treatment and 
aimed at preventing or delaying the recurrence of cancer. Clinically, hormone can be 
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injected into the patient's body orally, intravenously or intramuscularly. The 
resistance to hormonal therapy was reported clinically. Survivin, a new member of 
lAP family, conferred resistance to antiandrogen therapy through IGF-1 signaling 
[Zhang et.al., 2005]. The overexpression of human epidermal growth factor receptor-
2 (HER-2) weakened the antiproliferative effect of endocrine therapy for breast 
cancer [Dowsett, 2001]. 
1.1.2 Hypoxia/reoxygenation and its correlation with treatment resistance 
When a tumor proliferates much faster than the vasculature, it will not receive 
enough oxygen due to diffusion limit of oxygen within tissues. This phenomenon is 
called hypoxia. Normally, it refers to a condition in which the oxygen tension is less 
than lOmmHg (1.3%) and usually found in solid tumors. If the oxygen level drops 
even lower, the tumor cells will become necrotic and die (Fig. 1.1.1). Occasionally, 
the hypoxic region of the solid tumor may become oxygenated again due to the 
formation of new blood vessels. The physiology of hypoxic cells is somehow 
different from the hypoxia/reoxygenated cells. Adenosine triphosphate (ATP) is lost 
in ischemic tissues and results in failure of anaerobic glycolysis and the cells die 
through necrosis. On the other hand, reperfusion restores the ATP pool inside the 
cells that lead to additional losses of cells through apoptosis [Saikumar et.al., 1998]. 
One group of scientists revealed that the reoxygenation following hypoxia protected 
myocytes against apoptosis and increased the survival rate of myocytes and this was 
contributed by the reduced peroxynitrite (ONOO(-)) formation [Wang et.al., 2006]. 
Since the effect of reoxygenation following hypoxia remained unclear, further work 
was therefore needed. 
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The hypoxic tumor usually inherits resistance towards various kinds of 
therapies. It is less sensitive to radiotherapy due to the decrease in oxygen-free 
radicals which are the main component to produce DNA damage to cells. Brizel DM 
has pointed out the tumor hypoxia adversely affects short term clinical radiation 
response of head and neck cancer lymph node metastases [Brizel et.al., 1997]. Also, 
the tumor is resistant to chemotherapy because of limited delivery of drugs by 
circulation. 
Expanding Hypoxic Necrotic • 
••• tumour cells celts ceils capillary 
Fig. 1.1.1 A schematic diagram representing how the limited oxygen diffusion 
creates the hypoxic and necrotic regions in solid tumor. [Brahimi-Hom et.al.，2007] 
1.1.3 Aim of the study 
As scientists become more and more concerned about the relationship 
between the condition of microenvironment and the treatment resistance in solid 
tumors, the objective of the present study is to figure out the resistance mechanisms 
to chemotherapy in hypoxia/reoxygenated cancer cells. Throughout the study, two 
human cancer cell lines were used: hepatocellular carcinoma cells (HepG2) and 
squamous carcinoma cells (A431). First of all, the sensitivity of 
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hypoxia/reoxygenated cells towards various kinds of drugs were examined (Chapter 
2) so as to find out if there were any differences in the susceptibility to the drugs 
between hypoxia/reoxygenated cells and their parental cells. Interestingly, 
hypoxia/reoxygenated cancer cells were found to be resistant to several drugs. 
Among all, the resistance mechanisms of two selected drugs, doxorubicin and 
cisplatin, were further investigated (Chapter 3 and 4) respectively. Besides their 
frequent use clinically in treating a broad range of cancers, numerous reports of 
treatment resistance also urged us to examine the mechanism of treatment resistance. 
It was suggested that hypoxia/reoxygenated cancer cells underwent a different 
apoptotic pathway. Therefore, it is worth knowing whether this difference could lead 
to resistance towards particular drugs. Interesting results were obtained and 
elucidated (Chapter 5). All in all, it was hoped that the experimental findings could 
help us to improve the effectiveness of cancer treatment by modifying the present 
therapy or designing novel target-specific drugs. 
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Chapter 2 
The Drug Sensitivity in HepG2 Cells and A431 Cells 
2.1 Introduction 
According to the World Health Organization (WHO), 7.6 million people died 
from cancer which accounted for 13% of the total number of deaths worldwide in 
2005. There is an urge to develop suitable treatments for this leading and devastating 
disease so as to save more lives. Among all types of cancer, lung, stomach, liver, 
colorectal and oesophagus cancers are the top five common cancers for male while 
breast, lung, stomach, colorectal and cervical cancers are the most frequent cancer 
types for female. 
2.1.1 Treatment of cancer 
In order to deal with cancers, various kinds of treatments are adopted 
nowadays including surgery, chemotherapy, radiotherapy and immunotherapy. If the 
tumor is in an early stage without metastases, surgery is the preferred option for 
treatment. For instance, removal of tumors of the pancreatic head and the 
periampullary region using pancreaticoduodenectomy [Michalski et.al, 2007]. 
However, surgery alone often cannot help curing cancer completely and so other 
kinds of therapies are chosen. 
Chemotherapy refers to the use of drugs to cure cancer. It works by killing 
cells through triggering apoptosis, or, stopping or retarding growth of cancer cells 
through interfering cell division. Except using chemotherapy alone, it is usually 
administered along with other therapy. Sometimes, chemotherapy reduces the size of 
tumor before subjecting to surgery or radiation therapy and this is called neo-
adjuvant chemotherapy. Conversely, if drugs were taken after surgery or radiation 
therapy, this is called adjuvant chemotherapy. Although chemotherapy is so effective 
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in treating neoplastic diseases, side effects often exist such as nausea, vomiting and 
hair loss. In a worse case, drug resistance may even appear. 
2.1.2 Drug resistance 
The anticancer drug resistance can be divided into two classes: host factors 
and genetic or epigenetic alterations in the cancer cells. The phenomenon involving 
simultaneous resistance to unrelated drugs is called Multidrug resistance (MDR). The 
mechanisms of MDR are not yet well defined. Diminishing of intracellular drug 
accumulation by ATP-binding cassette (ABC) transporters such as P-glycoprotein 
and multidrug resistance-associated protein (MRP), drug detoxification by 
glutathione-S-transferase, altered targets such as topoisomerase II and modification 
in apoptosis such as the Bcl-2 pathway have been implicated in the development of 
the phenotype of MDR [Ling, 1997]. Host factors refer to the poor absorption or 
delivery, and, enhanced metabolism or excretion of a chemotherapeutic agent. In 
addition, the environmental conditions around the tumors like the extracellular 
matrix or tumor geometry also contribute to drug resistance [Perez-Tomas, 2006]. 
Other than MDR, the microenvironment is also an important factor in inducing drug 
resistance. Acidosis, hypoxia and increased glycolysis are the typical host factors 
commonly found in the tumor microenvironment. 
In this project, the relationship between hypoxia/reoxygenation and the 
sensitivity of chemotherapy were studied including the resistance mechanism of 
particular drugs in order to help designing novel drugs or new treatment for the 
chemotherapy-resistant cancers. Human hepatocellular carcinoma HepG2 cells and 
human squamous carcinoma A431 cells were used in the present study. 
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2.2 Materials and Methods 
2.2.1 Cell culture 
Human hepatocellular carcinoma HepG2 cells were cultured in Dulbecco's modified 
essential medium (DMEM) supplemented with 5% fetal bovine serum (FBS) 
(Invitrogen , Carlsbad CA, USA) while human squamous carcinoma A431 cells were 
supplemented with 10% fetal bovine serum. The cells were incubated in humidified 
incubator with 10% CO2 at 37^C. 
For HepG2 cells, two hypoxia/reoxygenation sublines, GIOHR and G20HR, were 
prepared. Firstly, the HepG2 cells were subjected to hypoxia for 96 hours followed 
by reoxygenation and regrow to 70% confluence. Then, the cells were passed twice 
under normoxia. Afterwards, the cells were subjected to the hypoxia/reoxygenation 
treatment again. The GIOHR cells were derived from 10 cycles of 
hpoxia/reoxygenation treatment, while G20HR cells were derived from 20 cycles of 
hypoxia/reoxygenation treatment. Similarly, two hypoxia/reoxygenation sublines, 
namely AlOHR and A20HR, were prepared. The AlOHR cells were derived from 10 
cycles of hpoxia/reoxygenation treatment, while A20HR cells were derived from 20 
cycles of hypoxia/reoxygenation treatment. Stocks of all the cell lines were prepared 
and stored in liquid nitrogen tank. The cell lines were discarded and thawed from the 
stock when they reached passage 15. All the assays beyond were performed in air. 
2.2.2 Drugs 
Cisplatin, carboplatin, doxorubicin, etoposide, hydrogen peroxide, methotrexate, 
paclitaxel and vincristine were purchased from Sigma. Camptothecin, 10-hydroxy 
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camptothecin and TNF alpha were purchased from Merck. Interferon alpha (IFNa) 
and interferon gamma (IFNy) were purchased from Millipore. 
2.2.3 MTT assay 
To test the sensitivity of cells towards different kinds of drugs, MTT cell survival 
assay was performed. Briefly, the cells were seeded in 96-well plates with a density 
of 1500 cells/well for HepG2 cells or a density of 500 cells/well for A431 cells for 2 
days and then drugs with various concentrations were added to the cells and 
incubated for 5 days. After the drug treatment, the medium in the wells was aspirated 
and replaced with 50fal Img/ml 3-(4, 5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, MO, USA) solution. The 
cells were incubated for an additional 3 hours so that the yellow MTT solution can be 
reduced to insoluble purple formazan by the mitochondrial dehydrogenase which 
was present in the viable cells. Finally, 150|il dimethyl sulfoxide (DMSO) was 
added to each well in order to dissolve the insoluble purple formazan and form a 
colored solution. The absorbance of each well was measured at 570nm by a 
spectrophotometer (Molecular Devices, Sunnyvale, CA，USA). 
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2.3 Results 
23A The drugs to which GIOHR and G20HR cells were more resistant 
From the results in Fig.2.3.1a and 2.3.1b, HepG2 cells responded to cisplatin, 
carboplatin, camptothecin, 10-hydroxy camptothecin and methotrexate in a dose-
dependent manner. Furthermore, GIOHR and G20HR cells were more resistant to all 
of them than the parental HepG2 cells (GP). The IC50 of cisplatin for GIOHR and 
G20HR cells were about 2.88- and 2.63-fold of that for the GP cells, respectively. 
The IC50 of carboplatin for G20HR cells were about 1.66-fold of that for GP cells 
while that of GIOHR cells was more than 2-fold. The IC50 of camptothecin for 
GIOHR and G20HR cells were about 1.22- and 1.31-fold of that for GP cells, 
respectively. The IC50 of 10-hydroxy camptothecin for GIOHR and G20HR cells 
were both more than 2-fold of that for GP cells. The IC50 of methotrexate for 
GIOHR and G20HR cells were about 1.35 and 1.30 fold of that for GP cells 
respectively. 
2.3.2 The drugs of which GP, GIOHR and G20HR cells have similar response 
From the results in Fig.2.3.2 and 2.3.3, all the three HepG2 cell lines responded more 
or less the same to etoposide, hydrogen peroxide, paclitaxel, TNF alpha and 
vincristine in a dose-dependent manner. It is interesting that TNF alpha seemed not 
to pose any lethal effect on all the three HepG2 cell lines under the selected range of 
concentration. 
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Fig. 2.3.1a. The sensitivity of HepG2 cells to cisplatin and carboplatin as measured 
by MTT assay. - • - : parent cells; - • - : conditioned cells after 10 
hypoxia/reoxygenation cycles; - • - : conditioned cells after 20 
hypoxia/reoxygenation cycles. Viability was expressed as a percentage of an 
untreated control. Error bars showed the standard deviation of at least 3 experiments. 
* :p< 0.05 (between AP and AlOHR); #: p < 0.05 (between AP and A20HR) 
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Fig. 2.3.1b. The sensitivity of HepG2 cells to camptothecin，10-hydroxy 
camptothecin and methotrexate as measured by MTT assay. - • - : parent cells; - • - : 
conditioned cells after 10 hypoxia/reoxygenation cycles; — • : conditioned cells 
after 20 hypoxia/reoxygenation cycles. Viability was expressed as a percentage of an 
untreated control. Error bars showed the standard deviation of at least 3 experiments. 
*: p < 0.05 (between AP and AlOHR); p < 0.05 (between AP and A20HR) 
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Fig. 2.3.2. The sensitivity of HepG2 cells to hydrogen peroxide, paclitaxel, TNF 
alpha and vincristine as measured by MTT assay. - • - : parent cells; - • - : 
conditioned cells after 10 hypoxia/reoxygenation cycles; - A - : conditioned cells 
after 20 hypoxia/reoxygenation cycles. Viability was expressed as a percentage of an 
untreated control. Error bars showed the standard deviation of at least 3 experiments. 
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Fig. 2.3.3. The sensitivity of HepG2 cells to etoposide as measured by MTT assay.-
• - : parent cells; - • - : conditioned cells after 10 hypoxia/reoxygenation cycles;--
• -- : conditioned cells after 20 hypoxia/reoxygenation cycles. Viability was 
expressed as a percentage of an untreated control. Error bars showed the standard 
deviation of at least 3 experiments. 
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2.3.3 The drugs to which AlOHR and A20HR cells were more resistant 
From the results in Fig 2.3.4a and 2.3.4b，A431 cells responded to carboplatin, 
doxorubicin, hydrogen peroxide and IFNa in a dose-dependent manner. Besides, 
AlOHR and A20HR cells were more resistant to all of them than their parental A431 
cells (AP). The IC50 of carboplatin for AlOHR and A20HR cells were both more 
than 2.5-fold of that for AP cells. The IC50 of doxorubicin for AlOHR and A20HR 
cells were about 1.08-fold and 1.21-fold of that for AP cells respectively. The IC50 
of hydrogen peroxide for AlOHR and A20HR cells were about 1.10- and 1.32-fold of 
that for AP cells respectively. The IC50 of IFNa for all the three A431 cell lines was 
undefined under the tested range of concentration. 
2.3.4 The drugs to which AlOHR and/or A20HR cells were more sensitive 
From the results in Fig 2.3.5, A20HR cells were more sensitive to camptothecin and 
vincristine than that of AP cells while both AlOHR and A20HR cells were more 
sensitive to methotrexate. The IC50 of camptothecin and vincristine for A20HR cells 
was about 0.63-fold and 0.55-fold of that for AP cells respectively. The IC50 of 
methotrexate for AlOHR and A20HR cells were about 0.67-fold and 0.53-fold of that 
for AP cells respectively. 
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2.3.5 The drugs which AP, AlOHR and AlOHR cells have similar response 
From the results in Fig 2.3.6a and 2.3.6b，all the three A431 cell lines responded 
more or less the same to 10-hydroxy camptothecin, cisplatin, etoposide, IFNy, 
paclitaxel and TNF alpha in a dose-dependent manner. Similar to HepG2 cells, TNF 
alpha seemed also to have less killing on any of the three A431 cell lines under the 
selected range of concentration. 
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Fig. 2.3.4a. The sensitivity of A431 cells to carboplatin, doxorubicin and hydrogen 
peroxide as measured by MTT assay. - • - : parent cells; - • - : conditioned cells 
after 10 hypoxia/reoxygenation cycles; - A - : conditioned cells after 20 
hypoxia/reoxygenation cycles. Viability was expressed as a percentage of an 
untreated control. 
* : p < 0.05 (between AP and AlOHR); # : p < 0.05 (between AP and A20HR) 
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Fig. 2.3.4b. The sensitivity of A431 cells to interferon alpha as measured by MTT 
assay. - • - : parent cells; - • - : conditioned cells after 10 hypoxia/reoxygenation 
cycles; : conditioned cells after 20 hypoxia/reoxygenation cycles. Viability 
was expressed as a percentage of an untreated control. 
p < 0.05 (between AP and AlOHR); #: p < 0.05 (between AP and A20HR) 
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Fig. 2.3.5. The sensitivity of A431 cells to camptothecin, methotrexate and 
vincristine as measured by MTT assay. - • - : parent cells; - • - : conditioned cells 
after 10 hypoxia/reoxygenation cycles; - A ~ : conditioned cells after 20 
hypoxia/reoxygenation cycles. Viability was expressed as a percentage of an 
untreated control. Error bars showed the standard deviation of at least 3 experiments. 
* : p < 0.05 (between AP and AlOHR); #: p < 0.05 (between AP and A20HR) 
21 
Sensitivity of A431 cells lines to IQ^hydrcgy camptothedn Semitmly of M31 oeMs lines to dsptotin 
120.00 — = 1 2 0 . 0 0 
- ^ A P ^•"AP 
100.00 丨 ^ ^ ^ 〜 O H R 100.00 ^ — 聽 
80.00 --——\ 80.00 
1 \ 1 t ^ 60.00 fU S 60.00 
4 0 . 0 0 ^ 4 0 . 0 0 \ 
20.00 f ^ ' ^ r ^ v ^ 20.00 
0.00 1 1 1 0.00 1 1 1 
0 . 0 0 2 0 . 0 0 4 0 . 0 0 60 .00 0 . 0 0 0 . 5 0 1.00 1.50 
Ctmcenteation of 10-hydroxy camtXotbedn (nM) Concoitratiai of dqjJatin (uM) 
Semitivity of M31cem lines toetoposkte 
120.00 -] 




承 60.00 ——I 
4 0 . 0 0 ^ 
I , 
20.00 —— 
0.00 -I 1 I 1 
0 . 0 0 zoo 4.00 6 .00 
ConcoHiatiati of etoijoside (uM) 
Fig. 2.3.6a. The sensitivity of A431 cells to 10-hydroxy camptothecin, cisplatin and 
etoposide as measured by MTT assay. - • - : parent cells; - • - : conditioned cells 
after 10 hypoxia/reoxygenation cycles; ： conditioned cells after 20 
hypoxia/reoxygenation cycles. Viability was expressed as a percentage of an 
untreated control. Error bars showed the standard deviation of at least 3 experiments. 
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Fig. 2.3.6b. The sensitivity of A431 cells to interferon gamma, paclitaxel and TNF 
alpha as measured by MTT assay. - • - : parent cells; - • - : conditioned cells after 
10 hypoxia/reoxygenation cycles; • : conditioned cells after 20 
hypoxia/reoxygenation cycles. Viability was expressed as a percentage of an 
untreated control. Error bars showed the standard deviation of at least 3 experiments. 
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2.4 Discussion 
Hypoxia/reoxygenation in solid tumors may change the physiology of 
carcinoma cells that make them even more adapt to the environment and survive. 
The altered gene and protein expressions probably contribute to the resistance 
towards different kinds of anticancer therapies. In order to have an insight on how to 
tackle the problem of chemotherapeutic resistance in solid tumors, the sensitivity to 
various kinds of drugs including those common in clinical use were studied in the 
selected cell lines. It consisted of platinum drugs (cisplatin and carboplatin), 
topoisomerase I inhibitors (camptothecin and 10-hydroxy camptothecin), 
topoisomerase II inhibitor (doxorubicin and etoposide), cytokines (interferon alpha, 
interferon gamma and tumor necrosis factor-alpha), antifolate drug (methotrexate), 
mitotic inhibitors (paclitaxel and vincristine) and oxidizing agent (hydrogen 
peroxide). 
The results obtained from the experiments revealed that both A431 cells and 
HepG2 cells had similar sensitivity towards tumor necrosis factor-alpha (TNFa) and 
paclitaxel no matter the cells were subjected to hypoxia/reoxygenation treatment or 
not. This was also true for the sensitivity of A431 cells towards interferon gamma. 
However, either or both of the HepG2 cells and A431 cells showed resistance 
towards other drugs to a certain extent. For doxorubicin resistance, it will be 
discussed in Chapter 3. For platinum drug-resistance, it will be discussed to Chapters 
4 and 5. For the remaining drugs, their structures, usages and resistance mechanisms 
will be discussed in the following. Table 2.4.1 showed the IC50 of various drugs 
tested in HepG2 cells and A431 cells while Table 2.4.2 summarized the sensitivity of 
drugs in HepG2 and A431 cells. 
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Table 2.4.1. The IC50 of 13 drugs tested in HepG2 cells and A431 cells. 
~ ^ ~ GIOHR G20HR A P A l O H R A20HR 
Cisplatin 0 . 8 | L I M 2 . 3 ^ i M 2 . 1 n M 0 . 2 3 | a M 0 . 2 3 | i M 0 . 2 5 | i M 
C a m p t o t h e c i n 1 0 . 8 n M 1 3 . 2 n M 1 4 2 r i M 1 2 . 8 n M 1 2 . 0 n M S.OnM 
10-hydroxy 
33.0nM >50.0nM >50.0nM 26.4nM 27.0nM 27.4nM 
camptothecin 
C a r b o p l a t i n 2 3 . 5 | i M > 5 0 . 0 | L I M 3 9 . 0 | i M 9 . 0 ^ i M > 2 0 . 0 | i M >20.0^M 
Doxorubicin ITO T^O ND 2 4 . 0 n M 2 6 . 0 n M 2 9 . 0 n M 
Etoposide 1.6|iM 2.0[xU L4|LIM0.78|LIM““0.88|iM0.92}aM 
H 2 O 2 4 0 . 5 ^ M 4 0 . 5 | L I M 3 9 . 0 一 2 5 . 0 ) A M 2 7 . 5 ^ M 3 3 % M 
Interferon >5000 >5000 >5000 
N D N D N D 
alpha U/ml U/ml U/ml 
Interferon >50.0 >50.0 >50.0 
N D N D N D 
gamma ng/ml ng/ml ng/ml 
M e t h o t r e x a t e 2 0 . 0 n M 2 7 . 0 n M 26.0nM 1 S.OnM lO.OnM S.OnM 
Paclitaxel 1 S . O n M 1 S.OnM I S . O n M 1 3 . 8 n M 1 3 . 2 n M 11.8nM 
>50.0 >50.0 >50.0 >50.0 >50.0 >50.0 
TNF alpha 
jig/ml fig/ml |ig/ml jig/ml ^ig/ml ^ig/ml 
Vincristine 1.6nM 1.6nM L6nM 2.9nM 2.9nM 1.6nM 
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Table 2.4.2. A summary of the sensitivity of 13 drugs in HepG2 and A431 cells. 
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(The table was constructed according to the value of IC50 and the graph plotted.) 
26 
2.4.1 Camptothecin and 10-hydroxy camptothecin 
Camptothecin is a pentacyclic alkaloid extracted from Camptotheca 
acuminate. It is a topoisomerase I inhibitor and kills carcinoma cells by stabilization 
of topoisomerase I cleavage complex and the formation of permanent DNA strand 
breaks. As shown in Fig. 2.4.1，camptothecin consists of a closed a-hydroxyl-5-
lactone ring which is the key component for cytotoxicity. As it is poorly soluble in 
aqueous media and inactivated easily by lactone ring hydrolysis，many different 
derivatives of camptothecin with improved solubility and potency have been 
developed like topotecan, irinotecan and SN-38 (Fig. 2.4.2). The action mechanism 
of camptothecin is primarily by the formation of a covalent topoisomerase-I-
camptothecin-DNA ternary complex known as the cleavage complex. This reversible 
complex cleavage is toxic to the cell only when it is collided with the replication fork. 
Consequently, a double-strand break formed that leads to an irreversible arrest of 
DNA replication at the replication fork. The cell death mechanism is then triggered 
(Fig. 2.4.3) [Liu et.al., 2005]. 10-hydroxy camptothecin is one of the novel analogs 
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Fig. 2.4.1. The structure of camptothecin [Rasheed and Rubin, 2003]. 
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Fig. 2.4.2. The structures of topotecan, irinotecan and SN-38. [Li et.al., 2006] 
Although it is so effective in treating a broad spectrum of cancers, resistance 
has been reported with the following proposed reasons: (1) overexpression of efflux 
pump ABCG2 [Ishikawa et.al., 2006]; (2) mutations in topoisomerase I [Chrencik 
et.al, 2004]; (3) cytotoxicity modulation by DNA repair enzyme 0(6-methylguanine 
DNA methyltransferase [Kuo et.al., 2006]; (4) downregulation of topoisomerase I 
[Eng et.al., 1990]; (5) alterations in the cellular response to the cleavage complex 
[Rasheed and Rubin, 2003]. 
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Fig. 2.4.3. Action mechanism of camptothecin [Liu et.al.，2005]. 
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Fig. 2.4.4. Structure of podophyllotoxin and etoposide. Etoposide consists of a 
glycosidic group substituted at the C-4 position, a polycyclic core (A-D rings) and a 
pendant ring (E-ring) [Baldwin and Osheroff, 2005]. 
2.4.2 Etoposide 
Etoposide is derived from a natural product called podophyllotoxin (Fig. 
2.4.4). It has been used to treat a variety of cancers such as small cell lung cancer, 
germ-line malignancies and leukemias. Its main target remains as topoisomerase II 
and works by stabilizing a covalent enzyme-cleaved DNA complex. In details, 
etoposide approaches a topoisomerase-DNA ternary complex through interacting 
directly with the ATP-bound topoisomerase II monomer and forms single-stranded 
or double-stranded DNA breaks at sites that have a cytosine one base 5' to the 
cleavage bond. Attaching to the complex, etoposide inhibits the ligation activity of 
topoisomerase II and the cleavage complexes are accumulated. Consequently, 
recombination/repair pathways, mutagenesis and chromosomal translocations are 
triggered. If the damage cannot be recovered, apoptosis will then be induced (Fig. 
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Fig. 2.4.5. A schematic diagram showing the effects of topoisomerase II-DNA 
cleavage complexes in cell [Baldwin and Osheroff, 2005]. 
The mechanism of etoposide resistance has been studied for a long time but it 
is still poorly understood. The mechanisms suggested include: (1) downregulation of 
topoisomerase II [Andoh et.al, 1996]; (2) mutation of topoisomerase II [Chan et.al., 
1993]; (3) overexpression of multidrug resistance-associated protein (MRP) gene 
[Schneider et.al.，1994]; (4) prevention of etoposide-induced apoptosis by fibroblast 
growth factor-2 (FGF-2) [Pardo et.al., 2002]; (5) induction of hypoxia-inducible 
factor-1 (HIF-1) alpha [Hussein et.al., 2006]; (6) loss of putative tumor suppressor 
gene EI24/PIG8 [Mork et.al., 2007]. 
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2.4.3 Hydrogen peroxide 
Hydrogen peroxide (H2O2) is a kind of reactive oxygen species (ROS) 
normally found in all aerobic organisms. It is mainly generated in mitochondria 
during oxidative phosphorylation and broken down by catalase and glutathione 
peroxidase. Hydrogen peroxide not only play a role in malignant transformation but 
can also play a role in triggering cell death. For carcinogenesis, hydrogen peroxide 
acts by inducing DNA damage, mutations and genetic instability. Nonetheless, 
hydrogen peroxide can also induce apoptosis in tumor cells. Moreover, experimental 
data have shown that drugs such as arsenic trioxide, which can increase the cellular 
levels of hydrogen peroxide, can effectively kill cancers cells. Although the issue is 
still controversial and direct administration of hydrogen peroxide was believed to be 
an inappropriate therapeutic strategy, the upregulation of cellular hydrogen peroxide 
by hydrogen peroxide-generating systems may be an alternative anticancer strategy 
[Lopez-Lazaro, 2007]. 
2.4.4 Interferons (IFN) 
Interferons are proteins secreted in response to stimuli and consist of at least 
five classes, being alpha, beta, gamma, tau and omega. This superfamily can be 
divided into two groups. Type 1 IFN consists of IFNa, IFNp，IFNu), and IFNx while 
type II only has IFNy [Caraglia et.al., 2005]. Traditionally, these proteins are used to 
protect the host against viral infection. However, they are becoming an important 
anticancer agent. 
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2.4.4.1 Interferon alpha (IFNoc) 
As mentioned before, IFNa is a type I interferon composed of 13 subtypes 
and is secreted nearly by all cell types. Nevertheless, all the subtypes share the same 
receptor system and function similarly. Apart from treating viral diseases like 
hepatitis C, IFNa was also used to treat hematological malignancies and solid tumors. 
Accordingly, the action mechanism of IFNoc is believed to directly inhibit the tumor 
cell proliferation in several ways including downregulation of oncogene suppression 
and upregulation of tumor suppressor genes. Additionally, IFNa also enhances the 
immune response by induction of MHC class I [Ferrantini et.al., 2007]. 
IFNa resistance has been investigated and reported for a long time. In most 
cases, the resistance was correlated with the signal transduction pathways activated 
by IFNa. Briefly, IFNoc activates the tyr kinase Jak-1 and Tyk-2 after binding to its 
surface receptor. Then, the downstream pathways of Jak-1 and Tyk-2 which involve 
the signal transducer and transactivator (STAT) proteins, phosphatidylinositol 3-
kinase (PI3K) and protein kinase C (PKC) were activated (Fig. 2.4.6) [Caraglia et.al, 
2005]. The suggested resistance mechanisms include defective Jak-Stat activation 
[Shang et.al., 2007], expression of COX-2 via STATl activation [Lee et.al.’ 2006]， 
and lack of STATl expression [Landolfo et.al., 2000]. 
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Fig. 2.4.6. Signal transduction pathway activated by IFNa [Caraglia et.al., 2005 . 
2.4.4.2 Interferon gamma (IFNy) 
IFNy is a type II interferon and is structurally different from IFNa. Similar to 
IFNa, IFNy also signals through Jak-Stat pathway. However, it binds to a different 
receptor called IFNy- receptor (IFNGR) and secreted from limited cell types 
including CD4+ T helper cell type 1 (Thl) lymphocytes, CD8+ cytotoxic 
lymphocytes, NK cells，B cells and professional antigen-presenting cells (APCs). 
IFNGR is constructed by two ligand-binding IFNGR2 chains and two signal-
transducing IFNGR2 chains. Mostly, IFNGR2 is limited and regulated by the state of 
cellular differentiation or activation [Schroder et.al., 2004]. Therefore, the cellular 
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level of IFNGR2 may be one of the key targets conferring chemotherapeutic 
resistance of IFNy. Likewise, alteration in Jak-Stat signaling pathway may also 
contribute to chemotherapeutic resistance of IFNy. Yet, few reports have discussed 
about its resistance in cancer therapy. 
2.4.5 Methotrexate 
Antifolates such as aminopterin and methotrexate were the first 
antimetabolites used clinically for more than 50 years (Fig. 2.4.7). It was used to 
treat only a narrow spectrum of cancers such as acute lymphoblastic leukemia, 
osteosarcoma and breast cancer. Methotrexate is now the only antifolate widely used 
in cancer therapy. The cellular target of methotrexate is the enzyme dihydrofolate 
reductase (DHFR) involved in folate metabolism. Inhibition of DHFR results in 
depletion of folate cofactor which is a key component of purines, thymidylate and 
amino acids. In addition, polyglutamation of MTX inhibits the action of folate-
dependent enzymes, thymidylate synthase, in thymidylate synthesis and glycinamide 
ribonucleotide formyltransferase in purine de novo synthesis. Since MTX has a polar 
glutamate side chain, it cannot pass through the cell membrane. Instead, it enters the 
cell either via a carrier-mediated system, the reduced folate carrier (RFC) or by 
membrane-associated folate receptors [Jansen and Pieters, 1998, McGuire, 2003]. 
Like other chemotherapeutic agents，resistance was also observed in MTX. It 
is reported that resistance may be due to decreased MTX uptake as a result of 
decreased RFC expression [Jansen and Pieters, 1998]. Besides, alteration of DHFR 
either in the expression or the affinity for MTX also contributes for the resistance. In 
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addition, suspected resistance determinants include low rates of thymidylate 
synthesis, impaired polyglutamylation, upregulation of the folate-cofactor and the 
availability of thymidylate and purines [Zhao and Goldman, 2003]. 
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Fig. 2.4.7. The structure of aminoptenn and methotrexate [McGuire, 2003]. 
2.4.6 Vincristine 
Vincristine is a natural alkaloid present in the leaf of the periwinkle plant 
Catharanthus roseus (L.) G. It has been used for anticancer therapy such as acute 
lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma for more than 30 
years. The molecular structure of vincristine is composed of a vindoline linked to a 
catharanthine (Fig.2.4.8). Vincristine is a mitotic inhibitor that interferes with 
microtubules function. At high concentration, it binds to tubulin to prevent mitotic 
spindle microtubules from polymerization resulting in microtubule disruption and 
inhibition of mitosis. At low concentration, however, it stabilizes the dynamics of 
microtubules and inhibits the segregation of chromosomes resulting in metaphase 
arrest and inhibition of mitosis [Gidding et.al, 1999]. 
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In vitro vincristine resistance has been investigated for a certain period of 
time. Among all the resistance mechanisms, overexpression of MDR protein such as 
P-glycoprotein [Huang et.al., 2008, Ohtani et.al., 2007], multidrug resistance-
associated protein (MRP) 1 [Grant et.al, 1994, Akan et.al., 2005] and lung resistance 
protein [Scheper et.al, 1993] was extensively reported. Besides, scientists also 
reported that vincristine resistance may also be related to the changes in tubulin 
isoforms that leads to a decreased binding affinity [Houghton et.al, 1985]，changes 
in the level of polymerized tubulin [Minotti et.al., 1991], changes in the stability of 
microtubules [Cabral and Barlow, 1989], induction of HIF-1 alpha [Hussein et.al., 
2006], etc. 
In most cases, HepG2 cells and A431 cells after hypoxia/reoxygenation 
treatment were found to be resistant towards the above mentioned drugs, except for 
camptothecin and vincristine in A431 cells. The proposed resistance mechanism of 
the mentioned drug in hypoxia/reoxygenation treated cells still need to be further 
investigated in order to confirm the exact resistance mechanism behind. Works such 
as examining the expressions of genes or proteins suspected to deal with resistance, 
knocking down or overexpressing the target genes and investigating the activities of 
various drug transporters can be done in the future. 
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Chapter 3 
The Resistance Mechanism of Doxorubicin in A431 
Cells 
3.1 Introduction 
Taking advantage of the success in genomics and proteomics researches, the 
treatment of cancer has been developed extensively in recent years. In the past, 
surgery and chemotherapy were the only ways of treating cancer. However, there are 
more kinds of treatment can be adopted to cure cancer nowadays such as radiation 
therapy, immunotherapy, hormonal therapy, monoclonal antibody therapy, etc. 
3.1.1 Chemotherapeutic resistance 
Chemotherapy refers to taking certain types of medicines to treat cancer. The 
medicines are usually worked by interfering cell cycle, disrupting DNA repair 
system or DNA synthesis so that cancer cells cannot grow or even die. Examples 
include paclitaxel which cures advanced breast cancer by interfering the breakdown 
of microtubule [Kumar, 1981], cisplatin which cures cervical cancer by forming 
DNA adducts and disrupting cell division [Tao et.al, 2008], and, docetaxel which 
cures hormone-refractory prostate cancer by affecting the assembly of microtubule 
and initiating apoptosis [Caffo et.al., 2008]. Although chemotherapy is so effective 
in treating various types of cancer, resistance always exists in certain patients or in 
particular circumstances. The failure of a specific type of chemotherapy may be due 
to poor absorption, rapid metabolism of the drug, alternations in genetic or protein 
expressions, reduced intracellular accumulation of the drug by efflux pump, inability 
of delivering the drug to the inner part of a bulky tumor or changing 
microenvironment of the tumor [Gottesman, 2002]. For instance, the overexpression 
of PDKlor Aktl in breast cancer cell leads to resistance to paclitaxel, doxorubicin 
and gemcitabine [Liang et.al., 2006], the presence of multidrug resistance protein 
(MRP) 1 and 3 contributes to the resistance towards methotrexate by reducing the 
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intracellular accumulation of the drug [Zeng et.al., 2001], the loss of putative tumor 
suppressor genes EI23/PIG8 confers resistance to etoposide through aberrant p53-
dependent apoptosis [Mork et.al” 2007]. In order to deal with chemotherapeutic 
resistance, we can either search for novel drugs or modify the present treatments by 
evaluating resistant mechanisms behind. 
3.1.2 Tumor hypoxia 
The alternation in genetic or protein expressions of carcinoma cells was 
proposed to be affected by tumor hypoxia. Hypoxia refers to a condition in which the 
oxygen tension is less than lOmmHg (1.3%). Hypoxia is usually observed in most 
solid tumors because this kind of tumor has limited vasculature resulting in poor and 
fluctuating blood flow. Cells in hypoxic regions have nutrient deprivation that 
induces cell cycle arrest and slower proliferation rate. Moreover, they alter gene 
expression so as to survive. For example, the increase in the expression of 
dihydrofolate reductase in response to transient hypoxia [Rice et.al., 1986]，the loss 
of D N A mismatch repair genes [Kondo et.al.，2001], the up-regulation of P-
glycoprotein [Comerford et.al., 2002], etc. Thus, tumors subjected to hypoxia usually 
exhibit drug resistance compared with the normal tumors due to the changes in the 
expression of gene-encoding protein. 
3.1.3 Structure and function of doxorubicin 
Doxorubicin, one of the well-known anthracyclines produced from 
streptomyces species, has been utilized clinically for treatment of cancer for more 
than 30 years. It is a weak base and has a planar cyclic anthraquinone nucleus 
attached to an amino sugar (Fig. 3.1.1) [Dorte Nielsen et.al., 1996]. However, its 
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detailed mechanism of action is still ambiguous. It has been suggested doxorubicin 
exerts its cytotoxic effect by binding to nucleic acids and inhibiting D N A synthesis 
[Supino et.al., 1977], forming free radicals which cause the destruction of D N A 
[Bates and Winterboum, 1982]，crosslinking of D N A [Skladanowski and Konopa， 
1994], unwinding of D N A [Fomari et.al, 1994]，induction of D N A lesions via the 
inhibition of topoisomerase II [Ramachandran et.al., 1993], triggering apoptosis 
[Skladanowski and Konopa, 1993], and, initiating growth arrest by the disruption of 
cyclins [Ling et.al,, 1996]. 
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Fig 3.1.1. The structure of doxorubicin. R=CH20H [Dorte Nielsen et.al., 1996] 
3.1.4 Clinical use of doxorubicin 
Although it remains unclear how doxorubicin actually exerts its cytotoxicity, 
it was well-known to be used in treating a broad range of cancers. However, 
cardiotoxicity occurs after pro-longed use of doxorubicin. Hence, a new formula of 
doxorubicin was discovered which was named liposomal anthracyclines. This drug 
was encapsulated within liposome so that it can persist in circulation and only exerts 
its effect in the site of neoplastic cells. Two liposomal formulations of doxorubicin 
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available in market are liposome-encapsulated doxorubicin-citrate complex (LED-
Myocet®) and pegylated liposomal doxorubicin (PLD-Caelyx®) [Lorusso et.al, 
2007]. Mostly, doxorubicin is used to treat breast cancer. According to a recent 
report, PLD was the front-line treatment of recurrent/metastatic breast cancer 
[Adamo et.al” 2008]. Other than breast cancer, other types of cancer such as prostate 
cancer [Heidenreich et.al., 2004], acute myelogenous leukemia [Lu et.al., 2007] and 
advanced neuroblastoma [Inge et.al., 2004] are also treated by doxorubicin. Besides 
using doxorubicin solely in treating cancer, it was often administered in combination 
with other medicines to cure metastatic cancers. A report stated that metastatic 
urothelial carcinoma cured by the combination of doxorubicin, gemcitabine, 
paclitaxel and carboplatin, reached 56% overall response rate and a 15-month 
median survival [Barocas and Clark, 2008]. 
3.1.5 Mechanisms of doxorubicin resistance 
Like other drugs, resistance also exists for doxorubicin treatment and is 
multifactorial. (1) Existence of classic multidrug resistance plienotype (MDR). That 
means the presence of P-glycoprotein (P-gp) which extrudes doxorubicin. 
Consequently, it decreases the intracellular accumulation of doxorubicin. (2) Non-P-
gp-mediated M D R includes energy-dependent efflux pumps other than P-gp. 
Multidrug resistance-associated protein (MRP), Lung resistance-related protein (LRP) 
56 and P95 are examples. Like P-gp, these proteins also belong to ATP-binding 
cassette (ABC) transporters and work by pumping drugs out of the cell. (3) Shifting 
of drug distribution from nuclear to cytoplasmic. (4) The overexpression of 
glutathione transferases (GST) confers doxorubicin resistance through the formation 
of nucleophilic thioether or oxidation-reduction reactions. (5) Alternation of 
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topoisomerase II (TOPO II) either by downregulation of T O P O II m R N A level, 
enhanced T O P O II protein degradation, deletion of one allele of T O P O II, mutations 
of T O P O II or posttranslational modification, (6) Increased D N A repair. Among all 
the possible mechanisms, the overexpression of P-gp is the most characterized 
phenomenon for the resistance of doxorubicin [Nielsen et.al” 1996]. 
3.1.6 Structure and function of P-glycoprotein 
P-glycoprotein (P-gp), with a molecular weight of 170 kD, is one of the ATP-
binding cassette (ABC) transporters. There are 48 different A B C transporters which 
are classified into A to G based on sequence similarities. Each P-gp comprises two 
transmembrane domains and two ABCs (Fig. 3.1.2) and presents only in limited 
places such as liver, kidney and ovary. Besides, it only transports neutral and cationic 
hydrophobic molecules but not anionic ones. In macroscopic view, the two 
transmembrane domains function as a single transporter by interacting with each 
others' ATP sites and the major sites for the binding of chemotherapeutic molecules 
lie on transmembrane domains 4, 5, 6, 10，11 and 12. They can bind various classes 
of drugs including Vinca alkaloids, anthracyclines, antibiotics, and other cytotoxic 
agents like mitomycin and Taxol [Ambudkar et.al, 2003]. When one of the above 
molecules approaches the binding sites of P-gp, ATP hydrolysis is triggered at either 
one of the ATP sites and changes the shape of P-gp. In turns, the molecule is 
expelled from the cell [Ramachandra et.al., 1998]. 
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Fig. 3.1.2. The structure of P-glycoprotein. [Ambudkar et.al., 2003] 
P-gp is encoded by M D R l gene which is located on chromosome 7 at q21.1 
[Takara et.al, 2006]. With the size of 4.6kb，MDRl m R N A was proposed to be 
regulated by several transcription factors including a p53 element [Chin et.al., 1992], 
a complex ofNF-kappa B/p65 and c-Fos proteins [Ogretmen et.al., 1999], heat shock 
transcription factor 1 [Vilaboa et.al., 2000] and a steroid xenobiotic receptor element 
[Synold eA«/.,2001]. 
3.1.7 Drug resistance contributed by P-glycoprotein and the solution 
P-gp has been shown to confer drug resistance in cancer therapy. For example, 
P-gp extrudes daunorubicin in renal clear cell carcinoma [Soto-Vega et.al” 2008] 
and mediates the efflux of imatinib mesylate in chronic myelogenous leukemia 
[Illmer et.al., 2004]. In most cases, the overexpression of P-gp is the main cause of 
poor clinical result of chemotherapy. Table 3.1.1 shows some examples of P-gp 
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related drug resistance [Takara et.al., 2006]. Moreover, upregulation of mdrl level 
was found after chemotherapy (Table 3.1.2). 
Table 3.1.1. Correlation of M D R l expression with the response to chemotherapy in 
different types of cancer. CR: complete response [Takara et.al, 2006] 
MDRl expression 
Type of tumor 
Positive Ne^tive 
A M L 27% CR 73% CR 
Acute leukemia 33% Remission 74% Remission 
A M L 60% CR 92% CR 
A M L 44% CR 100% CR 
A M L 80% Resistant disease 64% CR 
Lymphoma 55% CR 47% CR 
Multiple myeloma 25% Response 75% Response 
Breast cancer 7% CR 23% CR 
SCLC 75% Response 86% Response 
Ewing's sarcoma 17% Response 67% Response 
So ft tissue sarcoma 55% CR 80% CR 
Neuroblastoma 46% CR 84% CR 
In order to overcome the problem of M D R caused by P-gp，scientists have 
designed some modulators to reverse the situation. Among all compounds, verapamil 
and cyclosporine are typical examples. Verapamil has been shown to reverse 
doxorubicin resistance in human ovarian cancer as early as 1980s [Rogan et.al., 
1984]. It is a calcium channel blocker and worked by inhibiting the efflux of 
doxorubicin molecules inside the carcinoma cells. Similarly, cyclosporine functions 
as a competitive substrate for the binding site of P-gp [Tamai et.al.，1990] and help 
improving the clinical treatment in patients [Sonneveld et.al., 1992]. 
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3.1.8 Epigenetic modulation of mdrl 
Recent studies focuses on numerous scientists were keen on studying the 
epigenetic modulation of mdrl. It has been suggested that D N A methylation 
regulates the expression of mdrl. In fact, genes such as cytokines [Szalmas et.al,, 
2008] and p53 [Pogribny et.al, 2002] have been found to be regulated by 
methylation. D N A methylation refers to the addition of a methyl group (CH3) to the 
deoxycytidine with the formation of 5 -deoxymethylcytidine in a CpG dinucleotide. 
This reaction is catalyzed by D N A methyltransferase (Fig. 3.1.3). M D R was found to 
be related to the alternations of methylation status of the chemotherapeutic 
responding genes. For example, hypermethylation at W T H 3 promoter region was 
linked to the M D R phenotype in drug-resistant breast cancer cells [Tian et.al., 2005]. 
Thus, the demethylating agents such as 5 ‘-aza-2‘-deoxycytidine (5-Aza-dC) may be 
used to re-express the silenced target genes and reverse the M D R phenotype. 
'乂、 I u ^ . I •丨 
Suh!.ti:it€^  J hftdurt?! I I 
o 
~~CH： —CM ： 
o H o H 
丨 3 . , rx 、‘• 
’ ‘ 十 I>NM I > 
+ + 
^ NH? 
’ J I、 ,, • fJ 
、 —〜 : ; i 。if H NH： N 
o c卜 J r, . — • 
-.0 o>-
S-.icK'rHi«t\l-l.-iiu'lliifKimt' |.VA、I) I hiiiiKN.^vit-iiu* 
Fig. 3.1.3. A schematic diagram representing the process of D N A methylation. 
Arrow indicates the place of methylation. [Sulewska et.al., 2007] 
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In this project, the sensitivity and mechanism of resistance towards 
doxorubicin in hypoxia/reoxygenation treated A431 cells were determined so as to 
provide an insight in designing a better treatment for curing doxorubicin-resistant 
solid tumors. 
Table 3.1.2. Expression of mdrl in clinical specimens before and after chemotherapy. 
Type of tumor Patient status Expression of MDR l 
AML De novo 65% 
Secondary 80% 
AML De novo 18% 
Relapse/refractory 33% 
Acute nonlymphoblastic leukemia „ . De'DO'vo 27% 
Relapse/refractory 64% 
De novo 26% 
Actue leukemia Relapse 35% 
Remission 30% 
De novo 57% 
Relapse 100% 
^^ ^ Pre-treatment 14% 
Post-treatment 26% 
, , , 1 . , , Pre-treatment 29% 
Multiple myeloma „ , 
^ ^ Post-treatment S ^ 
, , Pre-treatment 6% 
Multiple myeloma ^ ^ ^ ^ ‘ 
Post-treatment 
„ Pre-treatment 14% 
B 一 ancer Post-treatment 43% 
„ 1 Pre-treatment 9% 
Breast cancer „ …， 
Post-treatment 64% 
„ Pre-treatment 11% 
B 触 t cancer Post-treatment 30% 
^ . Pre-treatment 15% 
Ovarian cancer … ， 
Post-treatment 47% 
。 Pre-treatment 40% 
Sacroma Post-treatment 20% 
T T Pre-treatment 75% 
Bladder cancer “ ^ ^ 一， 
Post-treatment 80% 
,“广 Pre-treatment i i % 
CMS system cancer ^ 
Post-treatment 57% 
“ Primary ^ 
O s _ r _ Metastatic 50% 
� P r i m a r y 18% 
Soft tissue sarcoma „ , , 
Relapse ^ 
^ . , Pre-treatment 
Cervical cancer „ ^ ^ … 
Post-treatment 
AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CNS, central 
nervous system. Expression of MDRl is calculated by dividing the MDRl-positive 
specimens by the total specimens. [Takara et.al., 2006] 
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3.2 Materials and Methods 
3.2.1 Cell culture 
Preparation of human squamous carcinoma A431 cells can be referred to section 
2.2.1. All the assays performed beyond were in air. 
3.2.2 MTT assay 
Please refer to section 2.2.3. 
3.2.3 Reverse transcription polymerase chain reaction (RT-PCR) 
Total R N A was isolated from cells with or without the drug treatment by lysing the 
cells with TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). After 
the cells were lysed by pipetting up and down several times, R N A was extracted with 
1 -bromo-3-chloropropane (BCP) (Molecular Research Center, Cincinnati, OH, USA). 
Followed by precipitating R N A with isopropanol, the R N A pellet was washed once 
with 75% ethanol treated with diethyl cyanophosphonate (DEPC), air dried and 
dissolved in DEPC treated water by incubating at 55-60®C for 10 minutes. To assess 
the integrity of the total R N A extracted, an aliquot of the R N A sample was run on a 
1% denaturing agarose gel stained with ethidium bromide (EtBr). A sharp and clear 
18S and 28S rRNA bands represented an intact total RNA. After confirming the 
integrity of R N A , its concentration was measured by reading the absorbance at 
260nm and 1.2 fig of the total R N A was used to perform the reverse transcription. To 
begin with, total R N A was incubated with 0.3 |ig oligo dT (Invitrogen) for 5 minutes 
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at 70®C and then kept on ice for 2-3 minutes. Then, the first c D N A was synthesized 
by using M - M L V reverse transcriptase (Promega, Madison, WI, USA) in IX first 
strand R T buffer at 42®C for 60 minutes. The c D N A generated was used as a 
template for P C R amplification of the genes of interest. Primer sequences for human 
mdrl and P-actin genes were as follows respectively: for mdrl, 
5 ‘ G A A T C T G G A G G A A G A C ATGACC-3 ‘ (forward primer) and 
5 ‘ TC C A A T T T T G T C A C C AATTCC-3 ‘ (reverse primer); for p-actin, 5'-
G C G G G A A A T C G T G C G T G A C ATT-3 ‘ (forward primer) and 5'-
G A T G G A G T T G A A G G T A G T T T C G T G - 3 ‘ (reverse primer). PCR amplification of 
the above genes were performed in a 20^1 mixture containing lOOnM corresponding 
gene specific primers, IX PCR buffer, 2 m M MgCb, 200nM dNTP and 1.25U Taq 
D N A polymerase (Promega) with the following conditions: for mdrl, initial 
denaturation at 94®C for 2 minutes; 30 cycles of denaturation at 94®C for 30 seconds， 
annealing at 55®C for 60 seconds, and extension at 72®C for 90 seconds; and final 
extension at 72°C for 7 minutes; for p-actin, initial denaturation at 94®C for 2 
minutes; 25 cycles of denaturation at 94®C for 30 seconds, annealing at 55®C for 30 
seconds, and extension at 70°C for 40 seconds; and final extension at 70®C for 5 
minutes. The PCR products were electrophoresed on a 1.2% agarose gel stained with 
ethidium bromide and observed with an ultraviolet transilluminator. The band 
intensity was analyzed with Image J 1.40g. 
3.2.4 Western blot analysis 
Cells with or without the drug treatment were washed 3 times with cold PBS 
containing I m M sodium ortho-vanadate and the remaining solution was then 
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completely removed. Afterwards, the cells were lysed with 30-50|li1 lysis buffer 
consisting of 0.9X PBS, 21^g/ml Aproptinin, O.S^ ig/ml Leupeptin, 4.9mM MgCl2, 
I m M sodium ortho-vanadate, 1% Triton X-100 and I m M phenylmethanesulfonyl 
fluoride (PMSF) by scraping with a cell lifter. The cell lysate was then kept on ice. 
After all the cell lysates were collected, they were centrifuged at MOOOrpm at 4。C for 
7 minutes and the supernatant was then measured and transferred to a new 1.5ml 
microfuge tubes. Protein quantification was performed by transferring 0.5^ il 
supernatant of each sample in triplicate to a 96-well plate followed by Protein Assay 
using B C A Protein Assay Reagent (Pierce). Equal volume of 2X sodium dodecyl 
sulphate (SDS) sample buffer was added to the supernatant and boiled for 10 minutes 
so as to denature the protein extracted. Afterwards, 15-25|ig of protein samples were 
resolved in 8%, 12% or 15% SDS-polyacrylamide gel according to the size of the 
target proteins at 200V for 45 minutes and then transferred onto an Immobilon-P 
membrane (Millipore, USA) soaked with E-blot transfer buffer at 15V for 50 minutes. 
The membrane was incubated with 5% non-fat milk at 4®C overnight. In the 
following day, the membrane was washed with PBS-T (IX PBS with 0.1% Tween 20) 
twice and then incubated with primary antibody at room temperature for 2 hours. The 
membrane was washed with PBS-T twice again and then probed with the 
corresponding secondary antibody conjugated with horseradish peroxidase (Zymed, 
USA) in 1:10000 dilution for 1-2 hours. The membrane was washed with PBS-T 
twice again and the signals were developed by using ECL Western Blotting 
Detection Reagents (Amersham Biosciences, UK). Finally, the signals were 
visualized on an X-ray film (Fuji Photo Film, Japan). The band intensity was 
analyzed with Image J 1.40g. 
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3.2.5 Doxorubicin efflux assay 
Since doxorubicin has intrinsic fluorescent property, the intracellular doxorubicin 
accumulation was determined by flow cytometric analysis. In brief, A431 cells were 
seeded with a density of 2x10^ on 3 5-mm dishes for 2 days. Before the addition of 
doxorubicin, cells were pretreated with 50|liM verapamil for 2 hours. Afterwards, the 
cells were treated with 2|xM doxorubicin at 37®C for 4 hours to allow rapid influx of 
drug. Cells were then harvested by trypsinization, washed once with IX PBS and 
resuspended in IX PBS. The fluorescent intensity of doxorubicin was measured at an 
excitation wavelength of 585nm (PE) by a FACSCanto flow cytometer (Becton 
Dickinson, Mountain View, Calif). Intracellular doxorubicin accumulation was 
measured and expressed in fluorescence units. Data collected were analyzed using 
software WinMDI 2.8. The percentage of doxorubicin accumulation was calculated 
as the ratio between the normalized peak channel value of cells without the exposure 
to verapamil or doxorubicin and that of the cells with the above treatment. 
3.2.6 Drug sensitivity of A431 cells treated with verapamil 
A431 cells with a density of 1000 cells/well were seeded on 96-well plates for 24 
hours and then various concentrations of doxorubicin together with 30jLiM verapamil 
were added to the cells and incubated for 72 hours. M T T assay was performed 
according to 3.2.2. 
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3.2.7 Treatment with DNA methyltransferase inhibitor 
A431 cells were seeded with a density of 2x10^ on 60-mm dishes for 2 days. Cells 
were then treated with IfiM, SjiM or lOjiM 5‘-aza-2‘-deoxycytidine (5-Aza-dC) 
(Calbiochem, USA), a D N A methyltransferase inhibitor, for 24 hours. Total R N A 
was then isolated for RT-PCR (protocol refers to 3.2.3). 
3.2.8 Drug sensitivity of A431 cells treated with 5-Aza-dC 
A431 cells with a density of 1000 cells/well were seeded on 96-well plates for 24 
hours and then various concentrations of doxorubicin together with 5|aM 5-Aza-dC 
were added to the cells and incubated for 72 hours. M T T assay was performed 
according to 3.2.2. 
3.2.9 Methylation-specific PCR (MSP) 
Genomic D N A from A431 cells was extracted by DNAzol reagent and denatured by 
0.2M N a O H at 37®C for 10 minutes. Then, genomic D N A was subjected to bisulfite 
modification by incubating with lOmM hydroquinone and 3 M sodium bisulfate (pH 
5) at 5(fC for 16 hours. The bisulfite-modified D N A was purified and desulfonated 
with 0.3M N a O H followed by precipitation with ethanol and elution with water. 
Afterwards, M S P can be carried out and all the promoter sequences and PCR 
conditions were shown in Table 3.2.1. An initial PCR product was created with 
universal primers (Pan-S and Pan-AS) followed by a second nested PCR using 
methylation-specific primers (MSP-S and MSP-AS) and immethylation-specific 
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primers (USP-S and USP-AS). The PGR products for M S P and and USP were 
resolved in 2 % agarose gel electrophoresis. The percentage of mdrl promoter 
methylation was calculated as the percentage for the band intensity of the methylated 
P C R product to the sum of the band intensity of both methylated and unmethylated 
P G R products, i.e. M S P x 100% / (MSP+USP). The band intensity was analyzed 
with Image J 1.40g. 
3.2.10 Bisulfite genomic DNA sequencing 
The P C R product created with universal primers (Pan-S and Pan-AS) was resolved in 
2 % agarose gel, extracted with QiaexII gel extraction kit (Qiagen) and subcloned into 
pGEM-T easy vector (Promega, Madison, WI). Clones were picked up from each 
sample for D N A sequencing. 
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223 48�C, 30s(40) 
Pan-AS ACCTCTACTTCTTTAAACTTAAAAAAACC 
MSP-S CGAGGAATTAGTATTTAGTTAATTCGGGTCGG 
95 67^ C, 30s (5) + 
MSP-AS ACTCAACCCACGCCCCGACG “ �广 ^^ ,《、丄 
OD C, iUS (5) -T 
USP S TGAGGAATTAGTATTTAGTTAATTTGGGTTGG 62�C，30s (5) 




3.3.1 Drug sensitivity of A431 cells to doxorubicin 
Drug sensitivity of A431 cells to doxorubicin was examined by treating the cells with 
lOnM, 20nM, 30nM, 40nM or 50nM doxorubicin for 5 days followed by M T T assay. 
Fig. 3.3.1 shows that A431 cells responded to doxorubicin in a dose-dependent 
manner and AlOHR and A20HR cells were more resistant to doxorubicin than their 
parental A431 cells (AP). 
3.3.2 Expression profile of mdrl and P-glycoprotein in A431 cells 
Probably, the resistance to doxorubicin was due to extensive efflux of doxorubicin by 
P-glycoprotein (P-gp) and hence the protein level of P-gp in the above three cell lines 
was measured by Western blot analysis. Fig. 3.3.2B indicates that AlOHR had 
significantly higher expression level of P-gp while A20HR had slightly higher 
expression level of P-gp than that of A P cells. Importantly, the expression of mdrl 
was similar after 1 cycle of hypoxia/reoxygenation treatment in all the three A431 
cell lines. Since P-gp is encoded by mdrl gene, the mdrl m R N A expression level 
should also be higher in both AlOHR and A20HR cells than that of A P cells. From 
the results of RT-PCR shown in Fig. 3.3.2A, the m R N A expression level of mdrl 
was found to be much higher in both AlOHR and A20HR cells than that in A P cells. 
The results show that the resistance of mdrl may be related to the high level 
expression of P-gp. 
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Fig. 3.3.1. The sensitivity of A431 cells to doxorubicin as measured by M T T assay.-
• - : parent cells; - • - : conditioned cells after 10 hypoxia/reoxygenation cycles;-
• -- : conditioned cells after 20 hypoxia/reoxygenation cycles. Viability was 
expressed as a percentage of an untreated control. Error bars showed the standard 
deviation of at least 3 experiments. 
*: p < 0.05 (between A P and AlOHR); #: p < 0.05 (between AP and A20HR) 
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mdrl B3BEE3ESE3 
1.00 1.11 2.00 1.81 1.09 1.20 
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Fig 3.3.2. (A) The basal m R N A expression level of mdrl and (B) the basal protein 
expression level of P-glycoprotein in A431 cells. 72HR referred to the cells treated 
with 72 hours hypoxia followed by 24 hours reoxygenation. The band intensity was 
analyzed with Image J 1.40g and the numbers showed the relative expression of 
mdrl compared to the control (AP), which was designated as 1.00. 
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3.3.3 Dox efflux-pump activity in A431 cells 
The functional activity of P-gp can be measured by flow cytometry. Generally, these 
energy-dependent drug efflux pumps work by removing toxic drugs taken out of the 
cells. Hence, the more of these efflux pumps were expressed, the more of the amount 
of drugs was to be released to the extracellular space, resulting in low intracellular 
drug accumulation. Fig. 3.3.3 shows the doxorubicin curves which represent the 
intracellular accumulation of doxorubicin in A431 cells in different conditions. The 
shifting of the curve towards the right of the x-axis indicates more doxorubicin 
accumulation in the cells. After the incubation of A431 cells with 2\iM doxorubicin 
for 4 hours, more doxorubicin molecules were absorbed and retained inside A P cells 
compared with that of AlOHR and A20HR cells. This observation can be shown by 
the greater shifting of the curve towards the right in AP cells. In the presence of 
SOfiM verapamil, a calcium channel blocker that can block the activity of P-gp, 
fewer doxorubicin molecules were pumped out and hence more doxorubicin 
molecules were accumulated intracellularly, especially for the AlOHR and A20HR 
cells which express a higher level of P-gp than that of AP. The results of the efflux 
activity indicate P-gp functioned normally and almost corresponded to the protein 
expression level of P-gp. 
57 
AP 
Difference in Peak 
^ 1 value with control 
Control 0.00 
Verapamil 3.69 
I - 14.53 
m 广 广 Verapamil +Doxorubicin 22.71 
‘專x\ 
j j r ^ " ^ ~ ~ Vo-‘ Vo^ ‘ Vcr 
PE-A 
AlOHR 
to Difference in Peak 
^ value with control 
Control 0.00 
Verapamil 1.61 
I . 11.33 
���产广... Verapamil+Doxorubicin 21.63 
O • _ • • • • • • I I I I I 10^  10' 10- 10" 10" 
PE-A 
A20HR 
Difference in Peak 
蜀 1 value with control 
Control 0.00 
Verapamil 3.33 爸 �t 11.52 
> Verapamil+Doxorubicin 18.63 
。丨 —“ • I ' I I 111 ^  1 1—I~• • I • 11 . 1 1—”~~I • ' 111 
10'' 10' 10- 10" 10* 
PE-A 
Fig. 3.3.3. Intracellular accumulation of doxorubicin in A431 cells that were treated 
with 2|iM doxorubicin in the presence or absence of 50jiM verapamil. Red area ( • ) 
represents control without exposure to doxorubicin, black line (_) represents cells 
exposure to verapamil, green line ( ) represents cells exposure to doxorubicin, blue 
line (-) represents cells exposure to verapamil and doxorubicin. 
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3.3.4 Drug sensitivity of A431 cells in the presence of verapamil 
Without the addition of verapamil, fewer A P cells survived compared with that of 
AlOHR and A20HR upon the doxorubicin treatment because AlOHR and A20HR 
cells possessed more P-gp that removed larger amount of doxorubicin molecules out 
of the cells. However, when A431 cells were co-treated with doxorubicin and 
verapamil, most of the P-gp was blocked and more doxorubicin molecules were 
trapped inside the cells. Consequently, fewer A431 cells survived compared with that 
of A431 cells treated with doxorubicin only (Fig. 3.3.4). 
3.3.5 Expression profile of mdrl in A431 cells in the presence of 5-Aza-dC 
Previous studies had shown that the methylation status of promoters of many genes 
had some correlation with their expression levels. To see whether it was also true for 
mdrl, D N A methyltransferase inhibitor, 5-Aza-dC, was administered. When A431 
cells treated with I J L I M , 5| IM or l O f i M 5-Aza-dC, the m R N A expression of mdrl was 
progressively increased. For A P cells, the relative mdrl expression level was 
increased from 1.00 to 3.60. For AlOHR cells，the relative mdrl expression level was 
increased from 3.11 to 5.12. For A20HR cells, the relative mdrl expression level was 
increased from 4.22 to 5.36. The results proved that 5-Aza-dC induced the 
expression of mdrl and the expression of mdrl may be correlated with the 
methylation status of mdrl promoter in A431 cells (Fig. 3.3.5). 
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Fig. 3.3.4. The sensitivity of A431 cells to doxorubicin in the presence or absence of 
verapamil as measured by MTT assay. - • - : cells treated with doxorubicin only; - • 
- : ce l l s co-treated with doxorubicin and verapamil. Viability was expressed as a 
percentage of an untreated control. Error bars showed the standard deviation of at 
least 3 experiments. 
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Fig. 3.3.5. The basal m R N A expression level of mdrl in A431 cells treated with 5'-
aza-2‘-deoxycytidine (5-Aza-dC). The concentration of 5-Aza-dC was 0 p M , l|iM, 
5|aM or lOfiM. The band intensity was analyzed with Image J 1.40g and the numbers 
showed the relative expression of mdrl as compared to the control (AP), which is 
designated as 1.00. 
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3.3.6 Drug sensitivity of A431 cells in the presence of 5-Aza-dC 
In the presence of 5-Aza-dC, more A431 cells survived when they were subjected to 
doxorubicin treatment, especially for AP cells (Fig. 3.3.6). It is probably due to the 
increased expression of mdrl in A431 cells. According to the previous experiments, 
A P cells had lower expression of mdrl than that of AlOHR and A20HR cells, maybe 
because of their hypermethylation status of mdrl promoter. When AP cells were 
treated with 5-Aza-dC, the mdrl promoter changed from hypermethylated status to 
hypomethylated status resulting in increase in mdrl m R N A templates. Consequently, 
more P-gp were expressed which served as the efflux pumps to remove the incoming 
doxorubicin molecules and the fewer A P cells were killed. Therefore, A P cells had 
similar percentage of survival compared with AlOHR and A20HR cells when they 
were co-treated with 5-Aza-dC and doxorubicin. 
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Fig. 3.3.6. The sensitivity of A431 cells to doxorubicin in the presence or absence of 
5 ‘-aza-2‘ -deoxycytidine (5-Aza-dC) as measured by MTT assay. - • - : cells treated 
with doxorubicin only; - • - : cells co-treated with doxorubicin and 5-Aza-dC. 
Viability was expressed as a percentage of an untreated control. 
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3.3.7 Methylation status of mdrl promoter region 
To examine the methylation status of mdrl promoter region in A431 cells, M S P was 
performed. It was found that a higher percentage of CpG island was methylated in 
A P cells (62%) compared with that of AlOHR (54%) and A20HR (52%) (Fig. 3.3.7). 
With reference to the basal m R N A expression level of mdrl examined previously, it 
may be concluded that the methylation status of mdrl promoter region was inversely 
correlated with the mdrl expression level in A431 cells. 
3.3.8 Bisulfite genomic DNA sequencing of the mdrl promoter 
In order to quantify and further confirm the result of methylation-specific PCR, 
bisulfite genomic D N A sequencing of the mdrl promoter in A431 cells was 
performed. The result revealed that A P cells had a higher percentage of methylation 
at the CpG island of the mdrl promoter (82%) than AlOHR cells (27%) and A20HR 
cells (64%). For example, complete CpG methylation at -144, -134, -110 and -105 
CpG sites of mdrl promoter in AP cells whereas all the above CpG sites were 
immethylated in AlOHR cells. For A20HR cells, complete CpG methylation was 
observed only at -144 and -110 CpG sites. The methylation status at the CpG sites of 
the mdrl promoter seemed to correlate with the expression of mdrl in A431 cells 
(Fig. 3.3.2). The hypermethylation of the mdrl promoter was suggested to inactivate 
the expression of mdrl but the hypomethylation of the mdrl promoter seemed to 
boost the expression of mdrl. 
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Fig. 3.3.7. Methylation status of the promoter of mdrl gene in A431 cells by using 
methylation-specific PCR. U refers to the PCR product amplified by using 
immethylation-speciflc primer; M refers to the PCR product amplified by using 
methylation-specific primer. Control refers to a positive control proving the success 
of the bisulfite modification and methylation-specific PCR. The percentage of CpG 
methylation of mdrl promoter was represented by a bar chart below the bands. Error 
bars showed the standard deviation of at least 3 experiments. 
65 
A P 
8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 
, T T T GT T T f T A GTTTTT££AGG AATTA GTATTTA GTTAGTTC GGGTCGGG AGT / GTTATT 
- I 4 t - 1 3 t - 1 1 " - H T j 
uj I If J iin ii iy,f III iJybfM 
I . m , 丨 ！ ] |i 1 H , : |,J : 
I i ft I |l |;/I||H |j|| || i I I I 丨： 
111 ILL! l UlllilMlII IlILlIjIu 
A l O H R 
8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 
•TT GTTTT GT^ G T T T 丁 T 丁 G A G AATTh GTaTT T« GTTAATTTGGGTTGGGAGTi.GTTATTTGT 
-M l -131 -n i l -1115 
| j , 1 If , I L | l ii! I 
| | i | 
A 2 0 H R 
8 0 9 0 1 0 0 1 1 0 1 2 0 1 3 0 1 4 0 
i A T T T A A T T T G T T T C G T A G T T T T T T G . G G A A T T A G T A T T T A G T T A ^ T T ^ G G G T T G G G A G T A G T 
-lu -131 -nil -im 
i, 1 if. u L ‘ I ji I , 
J'j :ijy m j| 11 MM ''I 1J jjji I I || 
； J L � : J /lIIjII /mJlad.[i/dJ—IiL/hl:l^ “l/vi: i i i jl,i/ 
Fig. 3.3.8. Bisulfite genomic D N A sequencing of the mdrl promoter in A431 cells. 
Here showed part of the promoter sequence of mdrl with C p G sites at -144, -134,-
110 and-105. 66 
3.4 Discussion 
Although doxorubicin has been revealed to confer resistance in different 
cancers and its resistance mechanism has been extensively studied, there is still no 
defined pathway regarding the resistance mechansim to doxorubicin. Moreover, there 
is not much research work been done on the issue of doxorubicin resistance in 
hypoxia/reoxygenation treated squamous carcinoma cells. Therefore, in the present 
study, we investigated the sensitivity and resistance mechansim of doxorubicin in 
hypoxia/reoxygenation treated squamous carcinoma cells A431. 
From the M T T assay, AlOHR and A20HR cells were more resistant to 
doxorubincin than that of A P cells after 5 days treatment (Fig. 3.3.1). The resistance 
mechanism for doxorubicin was suggested to be multifacotrial: (1) overexpression of 
mdrl genes [Puhlmatin et.al., 2005]; (2) overexpression of apoptotic regulators 
[Suzuki et.al, 1998]; (3) alternation of genes involved in the peroxisome 
proliferator-activated receptors gamma pathway [Rajkumar and Yamuna, 2008]; (4) 
Induction by molecules like cyclooxygenase-2 [Singh et.al., 2008] and ceramide [Liu 
et.al., 2008], etc. Among all, the overexpression of mdrl was the most extensively 
investigated. Thereby, we hypothesized that the differences in sensitivity to 
doxorubicin was due to the differences in the expression level of mdrl. 
From the results of RT-PCR (Fig. 3.3.2), the level of mdrl m R N A in AlOHR 
and A20HR cells was higher than that in AP cells. In addition, the protein level of 
mdrl encoded P-gp in AlOHR and A20HR cells was shown to be higher than that in 
AP cells by Western blot (Fig. 3.3.2). These results were compatible with the 
sensitivity of the A431 cells to doxorubicin. In cells, P-gp functions as an energy-
dependent drug efflux pump to extrude doxorubicin. The higher the expression level 
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of P-gp, the larger the proportion of the intake doxorubicin molecules are extruded. 
The increased expressions of both the mdrl gene and P-gp were suspected to be 
contributed by hypoxia/reoxygenation. Previous report suggested that ambient 
hypoxia induced mdrl gene in a time-dependent manner [Comerford et.al, 2002]. 
However, we found that the expression of mdrl did not change much after one cycle 
of hypoxia/reoxygenation treatment. 
To further confirm the above results, the efflux pump activity of A431 cells 
was determined (Fig. 3.3.3). Flow cytometry revealed that the efflux pump P-gp 
functions properly to reduce the intracellular accumulation of doxorubicin. Since 
AlOHR and A20HR cells had more expression of P-gp, fewer doxorubicin molecules 
were trapped intracellularly than that of A P cells. That explained why more AlOHR 
and A20HR cells survived upon doxorubicin treatment than that of A P cells. 
Verapamil, which was a calcium channel blocker, were commonly used as a 
modulator to reverse M D R phenotype [Wu et.al” 2007]. Although this first 
generation reversal agent was not totally promising, it was often used clinically and 
the third generation modulators such as biricodar and laniquidar were developing and 
under clinical trials [Nobili et.al, 2006]. When the A431 cells were co-treated with 
verapamil and doxorubicin, more doxorubicin molecules were trapped intracellularly, 
especially for AlOHR and A20HR cells (Fig. 3.3.3 and 3.3.4). This was contributed 
by the blockage of P-gp by verapamil. In this case, verapamil was believed to have 
the ability to reverse doxorubicin resistance in human squamous carcinoma A431 • 
Whether a gene would be expressed or not was believed to be regulated by 
the methylation status of the promoter region of the gene. Hypermethylation of the 
promoter region of a gene was found to silence the transciption of that gene. In the 
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present study, the promoter of mdrl gene in A P cells was methylated to a greater 
extent than that of AlOHR and A20HR cells. According to some reports, a D N A 
methyltransferase inhibitor 5 ‘ -aza-2 ‘ -deoxycytidine (5-Aza-dC) can trigger 
demethylation of a gene. This phenomenon was also true for mdrl genes. David had 
pointed out that the addition of 5-Aza-dC led to the hypomethylation of the promoter 
of mdrl gene in MCF-7 human breast cancer cell which result in increased 
expression of mdrl [David et.al” 2004]. To check if the hypermethylation status of 
mdrl gene in A431 cells can be reversed, A431 cells were treated with 5-Aza-dC. 
The results showed that 5-Aza-dC up-regulated the m R N A level of mdrl gene in 
A431 cells (Fig. 3.3.5). In addition, A P cells became more resistant to doxorubicin 
treatment with the addition of 5-Aza-dC (Fig. 3.3.6). In order to confirm the 
hypothesis that the methylation of the mdrl promoter was correlated with the 
expression of mdrl promoter and the resistance to doxorubicin, methylation-specific 
P C R and bisulfite genomic D N A sequencing of mdrl promoter was carried out. The 
results proved that hypomethylation at the CpG sites of mdrl promoter in AlOHR 
and A20HR cells was somehow correlated with the enhanced expression of mdrl and 
conferred resistance to doxorubicin (Fig. 3.3.7 and 3.3.8). 
In conclusion, doxorubicin resistance observed in hypoxia/reoxygenation 
treated A431 cells was probably contributed by the higher expressions of mdrl gene 
and P-glycoprotein. Furthermore, hypoxia/reoxygenation treatment was suggested to 
trigger the demethylation of mdrl promoter in A431 cells so as to re-express more 
mdrl-encoded P-glycoprotein which confers resistance to doxorubicin. 
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Chapter 4 
The Resistance Mechanism of Cisplatin in HepG2 
Cells 
4.1 Introduction 
Cancer is a kind of disease in which normal cells are transformed into abnormal 
cells by events such as mutation and rapid division without any control. There are 
more than 100 different types of cancer. Except leukemia, all other cancers can form 
solid tumors which are masses of abnormal tissue originating from organs or soft 
tissues and normally do not contain fluid areas and cysts. 
4.1.1 Tumor hypoxia and chemotherapeutic resistance 
In most solid tumors, the condition so called hypoxia usually exists. It describes 
a place where the oxygen tension is lower than lOmmHg (1.3%). Indeed, the 
existence of hypoxia is mainly due to the abnormalities in tumor vasculature. Unlike 
the regular, ordered vasculature of normal tissues, the tumor vasculature is irregular, 
tortuous, have blunt ends and with sluggish flow [Brown and Giaccia, 1998]. Since 
the oxygen diffusion distance in solid tumors is around 100-150 \im, any tumor cells 
away from this extent will be hypoxic. Apart from the low oxygen level, nutrients 
and growth factors are also difficult to be transported for such a long distance from 
the vasculature. Also, the extracellular pH becomes lower. All these affects cell 
proliferation, differentiation, metabolism as well as cell cycle [Yasuda, 2008]. 
Ultimately, it leads to the poor prognosis in solid tumors such as non-small-cell lung 
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cancer [Koukourakis et.al., 2003], esophageal and gastric adenocarcinomas 
[Driessen et.al., 2006]，and head and neck squamous cancer [Wigfield et.al., 2008]. 
The efficacy of a drug treatment depends at least on the distribution of the drug 
within the solid tumors and this is mediated by the expressions of drug efflux pumps 
such as P-glycoprotein and multidrug resistance-related protein (MRP) 1. In addition, 
the functional gene mutations or epigenetic changes that alter the expression of gene 
or proteins which are the targets of the drug may be another important determinant 
for the drug efficacy. For example, hypoxia may lead to the loss of p5 3-mediated 
apoptosis [Graeber et.al, 1996], deficiency in D N A mismatch repair [Kondo et.al” 
2001] and upregulation of dihydrofolate reductase [Rice et.al., 1986]. All these 
changes are suspected to be mediated by hypoxia-inducible factor-1 (HIF-1) which is 
induced only during hypoxia and rapidly degraded during normoxic condition 
[Tredan et.al., 2007]. 
4.1.2 Cisplatin and its action mechanism 
Cisplatin is a platinum-based drug responsible for curing cancers such as head 
and neck cancer [al-Sarraf, 1994], ovarian cancer [Alberts, 1995] and testicular 
cancer [Hohnloser, 1996]. It is synthesized from potassium tetrachloroplatinate (II), 
K2[PtCl4] and the product is powder in yellow color (Fig. 4.1.1). Another example of 
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platinum-based drug is carboplatin, which was also a target drug in this project. 
The action mechanism of cisplatin is mainly based on its interaction with D N A 
that leads to apoptosis. When cisplatin enters the bloodstream, its chloride ligands 
are attacked by proteins in the blood plasma such as human serum albumin. 
Consequently, a larger proportion of cisplatin is deactivated. The remaining intact 
cisplatin then enters the target cells either by direct diffusion or through 
Cu-transporting proteins. Inside the cell, one of the chloride ligands of the cisplatin is 
replaced by water and become active. The active form of the cisplatin then reacts 
with the guanine of D N A to form a cisplatin-DNA adducts. Consequently, the 
distorted D N A is recognized by D N A binding proteins that either initiate D N A 
damage repair or trigger apoptosis (Fig. 4.1.2) [Alderden et.al., 2006]. It was found 
that the cytotoxicity of cisplatin was correlated with the level and persistence of 
cisplatin-DNA adduct. 
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Fig. 4.1.1. A schematic diagram showing the production process of cisplatin 
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Fig. 4.1.2. The action mechanism of cisplatin [Alderden et.al.’ 2006]. 
73 
4.1.3 Mechanisms of cisplatin resistance 
Generally, resistance is multifactorial. There is no exception for cisplatin. 
Cisplatin resistance can be acquired intrinsically or after the exposure to cisplatin. 
The resistance mechanism primarily deals with inhibition of apoptosis at any stages 
along the drug metabolic pathway. It either inhibits the formation of cisplatin-DNA 
adduct or signal transduction after the formation of adduct. To summarize the 
extensive experimental work done by scientists, the proposed mechanism of cisplatin 
resistance were as follows (Fig. 4.1.3): (1) reduced intracellular cisplatin 
accumulation by efflux pumps such as multidrug resistance-associated protein (MRP) 
2; (2) enhanced inactivation of cisplatin by thiol-containing molecules like 
glutathione (Fig. 4.1.4); (3) enhanced repair of D N A adduct by process like 
nucleotide excision repair (Fig. 4.1.5); (4) deficiency of mismatch repair (MMR); (5) 
dysfunction of tumor suppressor gene p53; (6) overexpression of HER-2/neu and 
activation of the PI3-K/Akt pathway (Fig. 4.1.6); (7) attenuation of Ras and M A P K 
signaling pathways (Fig. 4.1.7); (8) inhibition of apoptosis such as overexpression of 
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4.1.4 Mismatch repair genes 
Mismatch repair is a kind of D N A repair mechanism that corrects the replication 
errors including base-base mismatches and insertion/deletion mispairs. The mismatch 
repair genes in eukaryotic cells are mainly divided into two groups: MutS and MutL. 
M S H 2 , M S H 3 and M S H 6 belong to MutS while M L H l , M L H 3 , PMSl and PMS2 
belong to MutL. There are two types of MutS: MutSa (MSH2/MSH6 heterodimer) 
and MutSp (MSH2/MSH3 heterodimer). MutSa, which constitutes 80-90% of MSH2, 
recognizes both base-base mismatches and insertion/deletion mispairs but MutSp 
recognizes insertion/deletion mispairs only. On the other hand, there are three types 
of MutL: MutLa (MLH1/PMS2 heterodimer), MutLp (MLHl/PMSl heterodimer) 
and MutLy (MLH1/MLH3 heterodimer). MutLa, which accounts for 90% of MLHl， 
interacts with MutS heterodimers and activates the downstream repair process (Fig. 
4.1.9). For MutLp and MutLy, their involvement in repair process is uncertain 
[Modrich, 2006]. 
Defect in M M R genes will lead to microsatellite instability and defect in 
apoptosis which in turns contribute to drug resistance. Abundant reports suggested 
that the loss of M L H l expression may be possibly responsible for cisplatin resistance 
[Brown et.al.，1997, Strathdee et.al” 1999, Plumb et.al, 2000]. Other than MLHl， 
the mutation of M H S 2 and M S H 6 was linked to the tolerance of human T-cell 
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leukemia line to methylating agents [Levati et.al., 1998]. 
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Fig. 4.1.9. The process of recognition and mismatch repair by M M R genes [Modrich, 
2006]. 
4.1.5 Epigenome and drug resistance in cancer 
Epigenetic events have been found to be correlated with drug resistance in 
cancer recently. It is done by altering the gene expression without changing the D N A 
coding sequence that is inheritable through cell division. There are two types of 
epigenetic events: D N A methylation/demethylation and histone 
acetylation/deacetylation. D N A methylation is controlled by D N A methyltransferase 
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(DNMT). It was reported that hypermethylation of CpG islands, which are primarily 
found in the promoter region of a gene, was associated with the transcriptional 
silencing of the gene. In fact, each type of human cancer has its own pattern of gene 
hypermethylation that makes it resistance to chemotherapy. In such cases, the levels 
of tumor suppressor genes were usually downregulated by hypermethylation of the 
genes' promoter. The examples of silenced genes by this method include those for 
D N A repair (hMLHl), cell cycle control (pi4層)and apoptosis (caspase 8). 
On the other hand, histone acetylation is the post-translational modification of 
histone proteins by histone acetyltransferases and histone deacetylases (HDAC). It is 
generally agreed that histone acetylation induces nucleosome remodeling and 
transcription activation of the gene. In contrast, histone deacetylation is mainly 
responsible for chromatin condensation that leads to transcription repression of the 
gene [Kopelovich et.al., 2003，Suzuki et.al., 2007]. 
D N A methylation has an intimate relationship with histone deacetylation. 
Accordingly, D N M T s not only direct D N A methylation but also recruit H D A C s for 
histone deactylation, resulting in transcriptional repression of the gene. In order to 
make drug-resistant cells become chemosensitive to anticancer drugs once again, 
target genes such as tumor suppressors and apoptosis-related genes must be 
re-expressed by the use of inhibitors of D N M T and H D A C inhibitors. 
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5-aza-2‘-deoxycytidine (5-Aza-dC) and zebularine are examples of D N M T inhibitors 
(Fig. 4.1.10). These inhibitors trigger the hypomethylation of the gene and let the 
gene re-express. For H D A C inhibitors, trichostatin A and suberoylanilide 
hydroxamic acid (SAHA) are clinically used to cause hyperacetylation of histone 
proteins and re-activate the gene expression (Fig. 4.1.11). 
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Fig. 4.1.10. Structures of two D N M T inhibitors. [Kopelovich et.al, 2003] 
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Fig. 4.1.11. Structures of H D A C inhibitors. [Kopelovich et.al., 2003] 
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Epigenetic therapy has been shown to be a promising therapy in certain cancers 
such as resensitization of drug-resistant ovarian cancer cell lines to cisplatin by 
zebularine [Balch a/. ,2005] and reversal of drug resistance in human tumor 
xenografts by 5-Aza-dC [Plumb et.al., 2000]. Nonetheless, problems such as 
non-selectable gene activation and progressive silencing of demethylated promoter 
impede the development of epigenetic therapy. Therefore, tremendous work remains 
to be done so as to achieve successful epigenetic therapy against cancer. 
Although cisplatin resistance has been observed in different types of cancers 
both in vitro and in vivo, few reports correlate cisplatin resistance with 
hypoxia/reoxygenation and epigenome. In this part of the project, the resistance 
mechanism of cisplatin developed in hypoxia/reoxygenation treated HepG2 cells and 
its relationship with epigenome were investigated. 
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4.2 Materials and Methods 
4.2.1 Cell culture 
Preparation of human hepatocellular carcinoma HepG2 can be referred to 2.2.1. All 
the assays performed beyond were in air. 
4.2.2 MTT assay 
Please refer to section 2.2.3. 
4.2.3 Reverse transcription polymerase chain reaction (RT-PCR) 
Total R N A was isolated from cells with or without treatment by lysing the cells with 
TRI Reagent (Molecular Research Center, Cincinnati, O H , USA). After the cells were 
lysed by pipetting up and down several times, R N A was extracted with 
1 -bromo-3-chloropropane (BCP) (Molecular Research Center, Cincinnati, O H , USA). 
Followed by precipitating R N A with isopropanol, the R N A pellet was washed once 
with 75% ethanol treated with diethyl cyanophosphonate (DEPC) , air dried and 
dissolved in DEPC treated water by incubating at 55-60°C for 10 minutes. To assess 
the integrity of the total R N A extracted, an aliquot of the R N A sample was run on a 
1% denaturing agarose gel stained with ethidium bromide (EtBr). A sharp and clear 
18S and 28S rRNA bands visualized represented an intact total R N A . After 
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confirming the integrity of R N A , its concentration was measured by reading the 
absorbance at 260nm and 1.2|ig of the total R N A was used to perform the reverse 
transcription. To begin with, total R N A was incubated with 0.3 jig oligo dT (Invitrogen) 
for 5 minutes at l(fC and then kept in ice for 2-3 minutes. Then, the first c D N A was 
synthesized by using M - M L V reverse transcriptase (Promega, Madison, WI, USA) in 
IX first strand RT buffer at 42^C for 60 minutes. The c D N A generated was used as a 
template for P C R amplification of interest genes. The primers for the D N A mismatch 
repair genes were used as reported that reported previously [Chang D K et.al. 2000] 
and were shown in Table 4.2.1. The PCR products were electrophoresed on a 1.2% 
agarose gel stained with ethidium bromide and observed with an ultraviolet 
transilluminator. The band intensity was analyzed with Image J 1.40g. 
4.2.4 Oligonucleotide transfection 
The sequences of 21-nucleotide sense and antisense R N A were as follow: PMS2 
siRNA, 5‘-GGUUUCAUUUCACAAUGCA(dTdT)-3‘ (sense) and 5'-UGCAUUGUG 
AAAUGAAACC(dTdT)-3 ‘ (antisense); scramble siRNA, 5'-CCUACGCCACCAAU 
UUCGU(dTdT) (sense) and 5'-ACGAAAUUGGUGGCGUAGG(dTdT) (antisense). 
PMS2 siRNA was purchased from Qiagen while the validated, non-targeting, 
scramble siRNA (siRNA with scrambled sequence that was not homology to any 
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known human gene sequences) was purchased from Tech Dragon. Transient 
transfection of siRNA was carried out by using Oligofectamine™ reagent (purchased 
from Invitrogen) and followed the manufacturer's protocol. HepG2 cells with a 
density of 1500 cells/well were seeded on 96-well plates for 1 day until they reached 
30-50% confluence. Cells were then transfected with 20nmol PMS2 siRNA or 
scramble siRNA per well in serum-free medium for 4 hours. Finally, the cells were 
cultured using D M E M supplemented with 5 % FBS (Invitrogen , Carlsbad CA, USA) 
and incubated in a humidified incubator with 10% CO2 at 37®C. In the following day, 
cisplatin with various concentrations (0|iM, 0.1 }iM, 0.5(iM, IjiM, 2|iM and 5|iM) 
were added to the cells and the incubation was for 3 days. The viability of cells were 
determined by M T T assay (protocol refers to 4.2.2). To check the knockdown 
efficiency of PMS2 by siRNA, HepG2 cells with a density of 2x10^ were seeded on 
35mm plates for 1 day followed by transfection with 200nmol PMS2 siRNA or 
scramble siRNA per well in serum-free medium for 4 hours. The cells were then 
cultured in D M E M with 5% FBS for 1 day and the m R N A expression level of PMS2 
was determined by RT-PCR (protocol refers to 4.2.3). 
4.2.5 Treatment with DNA methyltransferase inhibitor 
HepG2 cells were seeded with a density of 2x10^ on 60-mm dishes for 2 days. Cells 
86 
were then treated with 5\iM or \0\iM 5-aza-2'-deoxycytidine (5-Aza-dC) 
(Calbiochem, USA), a D N A methyltransferase inhibitor, for 24 hours. Total R N A was 
then isolated for RT-PCR (protocol refers to 4.2.3). 
4.2.6 Drug sensitivity of HepG2 cells treated with 5-Aza-dC 
HepG2 cells with a density of 1500 cells/well were seeded on 96-well plates for 24 
hours and then various concentrations of cisplatin together with 5|aM 5-Aza-dC were 
added to the cells and incubated for 72 hours. M T T assay was performed according to 
4.2.2. 
4.2.7 Treatment with histone deacetylase inhibitor 
HepG2 cells were seeded with a density of 2x10^ on 60-mm dishes for 2 days. Cells 
were then treated with 0.2fiM or 0.5}iM trichostatin A (TSA) (Calbiochem, USA), a 
histone deacetylase inhibitor, for 24 hours. Total R N A was then isolated for RT-PCR 
(protocol refers to 4.2.3). 
4.2.8 Drug sensitivity of HepG2 cells treated with TSA 
HepG2 cells with a density of 1500 cells/well were seeded on 96-well plates for 24 
hours and then various concentrations of cisplatin together with 0.5|iM TSA were 
added to the cells and incubated for 72 hours. M T T assay was performed according to 
4.2.2. 
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Table 4.2.1. A list of PCR primer sequences and their conditions used in this project. 
Annealing 
Target gene Sequences Cycle 
temperature (®C) 
P-actin Forward 5 ' - T A C C A C T G G C A T C G T G A T G G A C T C - 3 ' 
55 25 
(MMR) Reverse 5 ‘ - T C C T G C T T G C T G A T C C A C A T C T G C - 3 ‘ 
Forward 5 ' - A C A A G G G G C T G G G T T A G C A A A A G - 3 ‘ 
MSH6 55 30 
Reverse S ' - A G T C A C C A T T C T C T T C C G C T T T C G - 3 ‘ 
Forward 5 ' - T T G G C A T A T A A G G C T T C T C C T G G C - 3 ' 
MSH2 55 30 
R E V E R S E S ' - T G C A A C C T G A T T C T C C A T T T C T G G - 3 ' 
Forward S ' - C A G G T T T C A T T T C A C A A T G C A C G C - 3 ‘ 
PMS2 55 30 
Reverse 5 ' - T T A C C T T C A A C A T C C A G C A G T G G C - 3 ‘ 
Forward S ' - T T C T C A G G T T A T C G G A G C C A G C A C - 3 ‘ 
MLHl 55 30 
Reverse 5 ' - C T T C G T C C C A A T T C A C C T C A G T G G - 3 ' 
Forward S ' - G A T G G C A T T T T C A C A A G G A T G G G - 3 ‘ 
MSH3 55 30 
Reverse S ' - C T G G C G G A T A A T G G G T G A C A A A C - 3 ‘ 
Forward S ' - G G C A A C A G T T C G A C T C C T T T C A A G - 3 ‘ 
PMSl 55 30 
Reverse 5 ' - T T G A T A C C C T C C C C G T T A T C T C G C - 3 ' 
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4.3 Results 
4.3.1 Drug sensitivity of HepG2 cells to cisplatin 
Drug sensitivity of HepG2 cells to cisplatin was examined by treating the cells with 
O.l^iM，0.5faM, l\xM, 2\iM or 5[xM cisplatin for 5 days followed by M T T assay. It 
was observed that all the HepG2 cells responded to cisplatin in a dose-dependent 
manner (Fig. 4.3.1). The IC50 of cisplatin for GIOHR and G20HR cells were about 
2.25- and 2.80-fold of that for GP cells, respectively. In order to find out if there was 
any relationship between cisplatin resistance and the activity of the M M R genes, the 
m R N A expression levels in HepG2 cells were determined. 
4.3.2. Expression profile of the MMR genes in HepG2 cells 
The m R N A levels of six M M R genes were investigated by RT-PCR. The results in Fig. 
4.3.2 showed that the m R N A levels of all the M M R genes except PMS2 were more or 
less the same among GP, GIOHR and G20HR cells. For PMS2, the m R N A expression 
level was progressively down-regulated in GIOHR and G20HR cells. It was 
hypothesized that the cisplatin resistance observed in GIOHR and G20HR cells was 
related to the down-regulation of PMS2. Hence, PMS2 was knocked down by the use 
of siRNA so as to see if PMS2 played a role in cisplatin resistance in GIOHR and 
G20HR cells. 
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Fig. 4.3.1. The sensitivity of HepG2 cells to cisplatin as measured by M T T assay. - • 
-:parent cells; - • - : conditioned cells after 10 hypoxia/reoxygenation cycles; 
--•-- : conditioned cells after 20 hypoxia/reoxygenation cycles. Viability was 
expressed as a percentage of an untreated control. Error bars showed the standard 
deviation of at least 3 experiments. 
*:p< 0.05 (between AP and AlOHR); #: p < 0.05 (between AP and A20HR) 
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4.3.3 Drug sensitivity of HepG2 cells to cisplatin after the knock-down of PMS2 
PMS2 was knocked down by the use of PMS2 siRNA (PMS2i). After PMS2i 
transfection, the m R N A level of PMS2 was found to be down-regulated to about 50% 
of the original expression level (Fig. 4.3,3), The results suggested the PMS2 siRNA 
successfully knock-down the expression of PMS2. Afterwards, the sensitivity of 
HepG2 cells to cisplatin after PMS2i transfection was examined (Fig. 4.3.4). 
Interestingly, G P cells, which possessed higher basal m R N A level of PMS2, became 
more resistant to cisplatin while GIOHR cells, which possessed lower basal m R N A 
level of PMS2, responded similarly to cisplatin after PMS2i transfection. It agreed 
with the hypothesis that down-regulation of PMS2 increased the cisplatin resistance in 
HepG2 cells. However, the reason for differences in the expression level of PMS2 in 
the three HepG2 cells remained unsolved. One of the possible ways to regulate the 
expression of a gene was epigenetic regulation. 
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Fig. 4.3.3. The m R N A level of PMS2 after PMS2i transfection in GP cells. 
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Fig. 4.3.4. The sensitivity of HepG2 cells to cisplatin after PMS2i transfection as 
measured by M T T assay. - • - : cells that have transfected by PMS2 siRNA ；- • - : 
cells that have transfected by scramble siRNA; - A : cells without any transfection. 
Viability was expressed as a percentage of an untreated control. Error bars showed the 
standard deviation of at least 3 experiments. 
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4.3.4 Expression profile of MMR genes in the presence of 5-Aza-dC 
D N M T inhibitor 5 -aza-2 ‘ -deoxycytidine (5-Aza-dC) was then utilized to examine the 
effect of D N A methylation, one of epigenetic events, in the regulation of PMS2. It 
was stated that D N M T inhibitor can block the activity of D N M T resulting in 
hypomethylation of the gene's promoter and re-expression of that gene. After the 
addition of 5-Aza-dC to the HepG2 cells, the PMS2 expression level of both G P and 
GIOHR cells was induced (Fig. 4.3.5). For the other 5 M M R genes, their m R N A 
expression levels seemed to remain more or less the same. 
4.3.5 Drug sensitivity of HepG2 cells to cisplatin after the addition of 5-Aza-dC 
The epigenetic up-regulation of PMS2 and the relationship between cisplatin 
resistance and PMS2 expression level was further confirmed by M T T assay. HepG2 
cells were co-treated with 5-Aza-dC and cisplatin for 3 days and the results were 
shown in Fig. 4.3.6. All the three HepG2 cell lines became more resistant to cisplatin 
in the presence of 5-Aza-dC. The increase in the % survival was about 10% to 20%. 
The results suggested that the m R N A level of PMS2 seemed to directly correlate with 
cisplatin resistance in HepG2 cells. That means, the lower the m R N A level of PMS2， 
the greater the cisplatin resistance in the cells. In addition, hypopxia/reoxygenation 
treatment may down-regulate the expression of PMS2 by D N A methylation. 
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Fig. 4.3.5. The m R N A expression levels of M M R genes in HepG2 cells with or 
without the presence of 5-Aza-dC. The expressions of individual genes were 
measured by RT-PCR. The band intensity was analyzed with Image J 1.40g and the 
numbers showed the relative expression of the gene compared to the control (GP or 
GIOHR)，which is designated as 1.00. 
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Fig. 4.3.6. The sensitivity of HepG2 cells to cisplatin in the presence of 5-Aza-dC. 
- • - : cells treated with cisplatin only ；- • - : cells co-treated with cisplatin and 
5-Aza-dC. Viability was expressed as a percentage of an untreated control. Error bars 
showed the standard deviation of at least 3 experiments. 
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4.3.6 Expression profile of MMR genes in the presence of trichostatin A 
Another type of epigenetic event was histone acetylation. It is well known that the 
activity of H D A C can be inhibited by H D A C inhibitors like trichostatin A and 
hyperacetylation of histone proteins re-express the target gene. After the 
administration of trichostatin A, the expression level of PMS2 was found to be 
up-regulated in GP and GIOHR cells respectively (Fig. 4.3.7). For the other 5 M M R 
genes, their m R N A expression levels seemed to remain more or less the same. 
4.3.7 Sensitivity of HepG2 cells to cisplatin after the addition of trichostatin A 
Similarly, the epigenetic regulation of cisplatin rsistance was further confirmed by 
M T T assay. HepG2 cells co-treated with trichostatin A and cisplatin was compared 
with HepG2 cells treated with trichostatin A only. Obviously, all the three HepG2 
cells became more resistant to cisplatin in the presence of trichostatin A (Fig. 4.3.8). 
Thus, hypopxia/reoxygenation treatment may also down-regulate the expression of 
PMS2 by D N A acetylation that confer cisplatin resistance in HepG2 cells. 
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4.4 Discussion 
Although cisplatin has been discovered and utilized clinically for more than 40 
years, there are still few other platinum-based compounds can replace it. Carboplatin 
and oxaliplatin are the only examples commonly used. However, there was an urge to 
find a new substitute for or modify cisplatin because of the increasing incidences of 
cisplatin resistance in cancer treatment. In addition, the side effects of cisplatin were 
severe including neurotoxicity [Verschraegen et.al., 1995], vascular toxicity [Icli et.al, 
1993] and nephrotoxicity [Arany and Safirstein, 2003]. Thus, continuous effort is 
required to identify the mechanism of cisplatin resistance so as to find a better way of 
using platinum-based drugs. 
In the present study，how hypoxia/reoxygenation controlled the epigenetic 
regulation of cisplatin resistance was determined. From the results of M T T assay (Fig. 
4.3.1), GIOHR and G20HR cells were found to be more resistant to cisplatin than that 
of GP cells. The resistance to cisplatin may be contributed by the 
hypoxia/reoxygenation treatment. Probably, hypoxia/reoxygenation affected the 
expressions of cisplatin-associated genes. Among a vast amount of genes, D N A repair 
genes have been suggested for some time to be important in directing cisplatin 
resistance. Dabholkar claimed that enhanced level of excision repair 
cross-complementation group 1 (ERCCl) may play a role in clinical resistance to 
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cisplatin [Dabholkar et.al, 1992]. Besides, Kishi reported that reduced M L H l 
expression was related to poor prognosis in esophageal cancers [Kishi et.al., 2003]. In 
our HepG2 cell lines, the basal m R N A expression level of PMS2 was progressively 
down-regulated in GIOHR and G20HR cells while the m R N A expression levels of the 
other five M M R genes were similar among all the three HepG2 cell lines (Fig. 4.3.2). 
After the knock down of PMS2 in GP cells, which had the highest basal level of 
PMS2 among the three HepG2 cell lines, GP cells became more resistant to cisplatin 
(Fig. 4.3.4). It seemed that the expression level of PMS2 correlated with the efficacy 
of cisplatin. In fact，the resistance to alkylating agents such as cisplatin was claimed to 
be associated with the reduction of PMS2 in human cancers such as breast cancer, 
melanoma [Francia et.al” 2005], ovarian cancer [Drummond et.al.’ 1996] and 
osteosarcoma [Perego et.al.’ 1999]. However, a report showed that there was no 
association between M M R inactivation and cisplatin resistance in ovarian cancer cell 
lines [Helleman et.al, 2006]. Thus’ further investigation of their relationship was 
needed. 
It was known that the expression patterns of numerous amounts of genes were 
changed under hypoxia. For example, the expression of pro-apoptotic gene Bnip3 was 
induced in the developing cortex by hypoxia [Sandau and Handa, 2007], the 
repression of M L H l and M S H 2 by hypoxia through shifting the activation of 
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c-Myc/Max to repression of Mad 1/Max [Bindra and Glazer，2007], etc. Other than 
gene mutation, epigenetic regulation was one of the possible mechanisms to alter the 
expression of a gene. Typically, epigenetic regulation of a gene can be brought by 
D N A methylation and histone deacetylation. For D N A methylation, hypermethylation 
of the promoter of a gene seemed to silence the expression of the gene. For instance, 
glutathione S-transferase PI [Zhang et.al., 2005]， 06-methylguanine-DNA 
methyltransferase ( M G M T ) [Nakagawachi et.al., 2003] and E-cadherin [Garinis et.al., 
2002] had been reported to be silenced by promoter hypermethylation. For histone 
deacetylation, hypoacetylation of histone proteins also seemed to silence the 
expression of a gene. For example, candidate tumor-suppressor gene DLECl was 
downregulated by histone hypoacetylation in human epithelial ovarian cancer [Kwong 
et.al” 2006]. Likewise, the m R N A expression levels of PMS2 in GP and GIOHR cell 
lines were re-expressed or up-regulated in the presence of D N M T inhibitor, 
5-aza-2‘-deoxycytidine (Fig. 4.3.5), or H D A C inhibitor, trichostatin A (Fig. 4.3.7). 
Furthermore, all the three HepG2 cell lines became more resistant to cisplatin after the 
addition of either one of the above inhibitors (Fig. 4.3.6 and 4.3.8). 
In conclusion, our results suggested that hypoxia/reoxygenation may direct the 
epigenetic down-regulation of PMS2 by D N A methylation and histone deacetylation, 
resulting in cisplatin resistance. Besides, the expression of PMS2 was inversely 
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correlated with the efficacy of cisplatin treatment. The hypothesis can be ftirther 
proved by methylation-specific PCR and Western blot analysis of histone proteins. 
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Chapter 5 
The Role of PMS2 in Cisplatin-induced Apoptosis 
5.1 Introduction 
Undoubtedly, cisplatin works by forming D N A adducts. However, the exact 
events of how cisplatin-induced D N A damage and thus translated into durg-mediated 
cellular effects were unclear. As mentioned by Siddik, cisplatin-DNA adducts 
activate several signal transduction pathways consisting of cell cycle arrest, D N A 
synthesis inhibition and apoptosis. Among the potential pathways, apoptosis is of the 
most interest. Up till now, cisplatin-induced apoptosis was only known to be 
initiated or facilitated by more than 20 candidate proteins prior to D N A adducts 
formation but the extent of each of these proteins contributed to apoptosis was 
uncertain. 
5.1.1 Apoptosis 
Apoptosis was first introduced by John Kerr in 1972 and described as the 
formation of apoptotic bodies from a cell. Precisely speaking，apoptosis is a process 
of controlled, regulated and programmed cell death and it is different from necrosis, 
which is an uncontrolled cell death leading to lysis of cells. Morphologically, distinct 
changes of cytoplasm, nucleus and plasma membrane were observed during the early 
stage of apoptosis. In the cytoplasm, the endoplasmic reticulum dilates and the 
cistemae swell to form vesicles and vacuoles. In the nucleus, chromatin condenses, 
aggregates into dense compact masses and is fragmented to form apoptotic bodies. In 
the plasma membrane, cell junctions are disintegrated and blebbing occurs. 
Eventually, the cell rounds up and shrinks [Lawen, 2003]. 
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Apoptosis is responsible for removal of damaged cell beyond repair, 
maintenance of homeostasis inside our body, tissue development and regulation of 
immune cells, etc. All these events are mediated by two extensively studied apoptotic 
pathways: the extrinsic or receptor-mediated pathway, and, the intrinsic or 
mitochondrial pathway. 
5.1.2 Extrinsic pathway of apoptosis 
Extrinsic pathway is triggered by binding of extracellular ligands to death 
receptors located on the plasma membrane of the cell. There are several kinds of 
death receptors: Fas, tumor-necrosis factor receptor (TNF-R) 1, death receptor (DR) 
4 and 5，CARl and p75. In Fas signaling pathway, the Fas ligand (FasL) binds to Fas 
upon T-cell activation and resulting in receptor trimerization. This signals the 
binding of Fas-associated death domain protein (FADD) to Fas. Together with pro-
caspase 8，a complex called death inducing signaling complex (DISC) is formed. 
DISC can transactivate pro-caspase 8 to active caspase 8 which then cleaves the 
executioner caspases such as caspase 3 and apoptosis starts (Fig. 5,1.1). 
5.1.3 Intrinsic pathway of apoptosis 
Intrinsic pathway is a mitochondria-dependent process that is activated by 
stress such as oxidative stress or cytotoxic drugs. Upon activation, BH3-only proteins 
such as B A D and BIM trigger the oligomerization of B A X and BAK. The 
mitochondrial potential is then lost and cytochrome c is released. In addition, second 
mitochondrial-derived activator of caspase (SMAC)/Diablo proteins are released into 
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the cytosol which bind to and deactivate inhibitor of apoptosis proteins (lAPs) so that 
apoptosis can proceed. The released cytochrome c binds to the Apoptotic Protease 
Activating Factor-1 (Apaf-1) and leads to the formation of apoptosome. The 
apoptosome then activates the pro-caspase 9 followed by other effector caspases. 
Eventually, the activated effector caspases cleavc the cellular substrates to carry out 
apoptosis (Fig. 5.1.1). 
5.1.4 Cisplatin-induced apoptosis 
The cisplatin-induced apoptosis seemed to involve p53. As reported by 
Jayaramaii, ！IMG proteins facilitated the binding of p53 to D N A upon recognition of 
D N A damage [Jayaraman et.al.’ 1998]. Afterwards, p53 transaciivated several kinds 
of genes such as the pro-apoptotic gene, Bax. Bax was then translocated from the 
cytosol to the mitochondria. The loss of mitochondrial potential released proteins 
such as cytochrome c which activated the pro-caspasc 9 and 3 substanlialiy and 
apoptosis ensued [Makin et.al” 2001], This apoptotic pathway depended on the 
Bax:Bcl-2 ratio. This ratio was increased when the apoptosis occurred [Del Bello 
et.al., 2001]. On the other hand, cisplatin-induced apoptosis also pioceeded through 
Fas receptor. Binding of FasL to Fas receptor activated caspasc R and CA'enlaally 
caspase 3，resulting in apoptosis (Fig. 5.1.2) [Micheau et.al.’ 1997]. This apoptotic 
pathway is also p53-dependent [Mulici et.al., 1998J. Alihougli both ciplalin-induced 
apoptotic pathways depended on p53, some reports suggested the rna I Hi act ion nrp53 
sensitizes tumor cells to cisplatin but not makes them more resistant [Fan et.al., 
1995]. 
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h ndogenoas ligand 
Apo?i IKAII 歡 I I f t 
Fig. 5.1.1 A diagram showing the process of apoptosis. (Adopted f rom the website of 
"http: / /www.biooncology.com") 
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5.1.5 M M R and apoptosis 
When the extent of D N A damage was beyond a critical threshold, apoptosis 
was triggered by M M R proteins. Nonetheless, there were still not much articles 
describing direct apoptotic signaling by M M R proteins. It has been reported that 
M S H 2 protein interacted with A T R and regulated the phosphorylation of Chkl 
[Wang and Qin, 2003]. 
The role of M M R proteins as a direct apoptotic signaling is still so loose. 
Besides, M M R proteins seem to be upstream signaling molecules participating in 
apoptosis. In the previous chapter, it was demonstrated that PMS2 played a critical 
role in the susceptibility of cisplatin treatment. W e proposed that PMS2 may act as a 
direct signaling molecule in cisplatin-induced apoptosis. Moreover, the 
hypoxia/reoxygenation treatment may alter the expression of signaling molecules 
along the cisplatin-induced apoptosis. 
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Fig. 5.1.2. The suggested pathways involved in cisplatin-induced apoptosis [Siddik, 
2003]. 
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5.2 Materials and Methods 
5.2.1 Cell culture 
Please refer to 4.2.1. All the assays performed beyond were in air. 
5.2.2 Flow cytometric analysis of apoptosis 
HepG2 cells were seeded with a density of 2x10^ on 60-mm dishes for 2 days and 
then treated with 2)iM cisplatin with or without the presence of P M S siRNA for 3 
days. Cells were then washed and collected in PBS and stained with 5|LI1 Annexin-V-
GFP fusion protein and Img/ml PI in binding buffer (lOmM HEPES, 140mM NaCl, 
2.5mM CaCl2) for 15 minutes at room temperature in dark. Apoptotic cells were 
stained by Annexin-V-GFP fusion protein with green fluorescence emission while 
the nuclei of the apoptotic cells were stained by PI with red fluorescence emission. 
The fluorescence signal of the cells was analyzed by FACSort cytometer and 10^ 
cells were read for each sample. Finally, the graphs were produced by software 
WinMDI 2.8 with the x parameter being FITC-A (Annexin-V-GFP fusion protein) 
and the y parameter being PerCP-Cy5-5-A (PI). 
5.2.3 Oligonucleotide transfection 
Please refer to 4.2.4. 
5.2.4 Western blot analysis 
Please refer to 3.2.4. 
I l l 
5.2.5 Drug and antibodies 
Cisplatin was purchased from Sigma. Antibodies targeting B-actin, Bcl-2, Bcl-xL, 
Bax, caspase 3, cytochrome c, F A D D and Fas were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Antibodies targeting BID, caspase 8 and caspase 9 
were purchased from Stressgen (San Diego,CA). Antibody targeting p53 was 
purchased from Oncogene. Caspase inhibitors 3, 8 and 9 were purchased from Merck. 
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5.3 Results 
5.3.1 Cisplatin induced apoptosis 
In chapter 4, it has been shown that GIOHR cells were more resistant to cisplatin 
than GP cells. It was known that cisplatin exerted its cytotoxicity by causing D N A 
damage and eventually leading to apoptosis. Thus, it was expected that the sensitivity 
of cisplatin may directly correlated with the extent of apoptosis. From the results of 
flow cytometry, fewer GIOHR cells were found to undergo apoptosis compared with 
that of GP cells (Fig. 5.3.1). 
5.3.2 Knockdown of PMS2 by siRNA 
As demonstrated in Chapter 4, PMS2 played a critical role in mediating cisplatin 
cytotoxicity. It was speculated that PMS2 may act as a direct signaling molecule in 
the cisplatin-induced apoptosis. Interestingly, fewer GP and GIOHR cells underwent 
apoptosis after the expression of PMS2 was knocked down by PMS2i transfection 
(Fig. 5.3.1). In order to further confirm the role of PMS2 in cisplatin-induced 
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5.3.3 Cisplatin-induced apoptosis involved caspases 
Before looking into the expression levels of apoptotic proteins, it was necessary to 
see whether caspases were involved in cisplatin-induced apoptosis. The inhibitors of 
the three common caspases, caspases -3, -8 or -9, were incubated together with 
cisplatin in the HepG2 cells and flow cytometry was performed. The result showed 
that fewer GP or GIOHR cells underwent apoptosis after the addition of either one of 
the above caspase inhibitor upon cisplatin treatment (Fig. 5.3.2, 5.3.3 and 5.3.4). In 
short, cisplatin-induced apoptosis involved caspases -3, -8 and -9. 
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Fig. 5.3.2. The cisplatin treatment in GP and GIOHR cells in the absence or presence 
of 30)liM caspase 8 inhibitor. 
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Fig. 5.3.3. The cisplatin treatment in GP and GIOHR cells in the absence or presence 
of 30|^M caspase 9 inhibitor. 
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Fig. 5.3.4. The cisplatin treatment in GP and GIOHR cells in the absence or presence 
of 30|aM caspase 3 inhibitor. 
118 
5.3.4 Protein expressions of anti-apoptotic genes 
In order to elucidate how GIOHR cells were adapted to cisplatin-induced apoptosis, 
both the expressions of anti-apoptotic and pro-apoptotic proteins were examined. For 
the anti-apoptotic proteins, they comprised Bcl-2 and Bcl-xL. By Western blot 
analysis, the basal expression of Bcl-2 in GIOHR cells was significantly higher than 
that of GP cells but the basal expression of Bcl-xL was more or less the same in GP 
and GIOHR cells (Fig. 5.3.5). 
5.3.5 Protein expressions of pro-apoptotic genes 
For pro-apoptotic proteins, they included p53, Fas, F A D D , Bax, Bid, cytochrome c, 
caspase 3, caspase 8 and caspase 9. Fas, F A D D and caspase 8 were mainly 
responsible for the extrinsic pathway of apoptosis while Bax, Bid, cytochrome c and 
caspase 9 were mainly responsible for the intrinsic pathway of apoptosis. Among 
them, down-regulation of Fas, F A D D , caspase 3 and caspase 9 was observed in 
GIOHR cells compared with that of GP cells. For Bax, Bid and cytochrome c, both 
GP and GIOHR cells had similar basal expression levels (Fig.5.3.6). Unexpectedly, 
the basal expression levels of p53 and caspase 8 were higher in GIOHR cells than 
that of GP cells. Taken along with the data showing fewer GIOHR cells underwent 
cisplatin-induced apoptosis than that of GP cells, it seemed that cisplatin-induced 
apoptosis proceeded through the extrinsic pathway. 
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Fig. 5.3.5. The basal protein expression levels of anti-apoptotic proteins in HepG2 
cells. The band intensity was analyzed with Image J 1.40g and the values indicated 
the relative expression of the proteins compared to the control (GP), which was 
designated as 1.00. 
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Fig. 5.3.6. The basal protein expression levels of pro-apoptotic proteins in HepG2 
cells. The band intensity was analyzed with Image J 1.40g and the values indicated 
the relative expression of the proteins compared to the control (GP), which was 
designated as 1.00. 
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5.3.6 Protein expressions of apoptotic proteins after knockdown of PMS2 
Up till now, no one had reported the role of PMS2 as a direct signaling molecule in 
cisplatin-induced apoptosis yet. Hence, PMS2 was knocked down by siRNA and see 
if its level affected the protein expression levels of apoptotic proteins. After the 
PMS2 level was knocked down, p53, Fas, F A D D , Bax, Caspase 8 and Caspase 3 
were down-regulate while only Bcl-2 was up-regulated. For Bid and caspase 9, the 
expression levels remained the same. 
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Fig. 5.3.7. The protein expression levels of apoptotic proteins in HepG2 cells after 
the knockdown of PMS2 by siRNA transfection. The band intensity was analyzed 
with Image J 1.40g and the numbers showed the relative expression of the proteins 
compared to the control (GP/GIOHR), which was designated as 1.00. The difference 
in the expression could be related to Fig. 5.3.5 and 5.3.6. 
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5.4 Discussion 
PMS2, which forms heterodimers with M L H l , is one of the mismatch repair 
genes responsible for post-replication correction of D N A mispairs. Extensive amount 
of reports were discussing the association of several diseases with the mutation of 
PMS2 which resulted in microsatellite instability. For instance, mutation in PMS2 
was well known to cause hereditary nonpolyposis colorectal carcinoma (Lynch 
syndrome) [Hendriks et.al., 2006], Turcot's syndrome [De Rosa et.al., 2000], and 
trigger the formation of cafe-au-lait spots that leaded to childhood cancers [Kratz 
et.al., 2008]. However, only a few reports were talking about the role of PMS2 as a 
direct signaling molecule to initiate apoptosis. Accordingly, PMS2 mediated the 
ionizing radiation-induced apoptosis via a p53-independent pathway [Zeng et.al., 
2000], stabilized p73 that enhanced D N A damage-induced apoptosis [Shimodaira 
et.al., 2003] and had p53-response elements that activated p53 upon severe D N A 
damage [Chen and Sadowski, 2005]. 
In the previous chapter, it has been demonstrated that the sensitivity of 
cisplatin was directly correlated with the expression of PMS2. At the moment, it 
further showed that the sensitivity of cisplatin was directly correlated with the extent 
of apoptosis in which fewer GIOHR cells were found to undergo apoptosis compared 
with that of GP cells (Fig. 5.3.1). In addition, knockdown of PMS2 in HepG2 cells 
led to the downregulation of ciplatin-induced apoptosis (Fig. 5.3.2). To summarize 
the above data, it was hypothesized that PMS2 may directly signal particular 
apoptotic protein(s) to initiate cisplatin-induced apoptosis. It was proven that 
cisplatin-induced apoptosis may depend on the activity of caspases such as caspases -
3, -8 and -9 (Fig. 5.3.2, 5.3.3 and 5.3.4). 
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In order to elucidate how PMS2 signaled the apoptotic protein and how 
hypoxia/reoxygenation treatment affected the cisplatin-induced apoptosis, the basal 
expression levels of apoptotic proteins and their corresponding expression levels 
after the knockdown of PMS2 were examined. Apoptotic proteins can be divided into 
two distinct groups: anti-apoptotic and pro-apoptotic proteins. Pro-apoptotic proteins 
are proteins that are responsible for initiating apoptosis by three types of stimuli: the 
deprivation of survival factors, signals generated upon ligand-receptor binding, or 
cell damaging stress [Jarpe et.al, 1998]. Examples of pro-apoptotic proteins include 
p53, Fas, F A D D , Bax, Bid, cytochrome c, caspase 3, caspase 8, caspase 9. In contrast, 
anti-apoptotic proteins are proteins that protect cells from undergoing apoptosis by 
blockage of caspase activity, inhibition of the pro-apoptotic proteins signaling, or 
removal of the apoptotic stimuli. Examples of anti-apoptotic proteins include Bel-2 
and Bcl-xL. 
From the results, the basal expression levels of pro-apoptotic proteins，Fas, 
F A D D , caspase 3 and caspase 9 in GIOHR cells were significantly lower than that in 
GP cells (Fig. 5.3.5). On the other hand, the basal expression levels of anti-apoptotic 
protein Bcl-2 in GIOHR cells was much higher than that in GP cells and that of Bcl-
xL was similar in both cell lines (Fig.5.3.6). Unexpectedly, the basal expression level 
of pro-apoptotic proteins, p53 and caspase 8, were much higher in GIOHR cells than 
that of GP cells which was contradicted to the results of the sensitivity of cislpatin 
treatment (Fig. 5.3.5). Generally, high basal expression levels of pro-apoptotic 
proteins together with low basal expression levels of anti-apoptotic proteins result in 
greater extent of apoptosis upon cytotoxic drug treatment. Therefore, it was 
suspected the p53 protein in GIOHR cells may be mutated as mutant p53 protein 
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function as anti-apoptotic protein. In conclusion, hypoxia/reoxygenation treatment 
seemed to down-regulate the expression levels of pro-apoptotic proteins and up-
regulate the expression levels of anti-apoptotic proteins which prevented GIOHR 
cells from carrying out apoptosis and made them more resistant to cisplatin therapy. 
After PMS2 was knocked down by siRNA transfection, the expression of Fas, 
FADD, Bax, caspase 8 and caspase 3 was reduced while the expression of Bcl-2 and 
was enhanced. For Bid and Caspase 9, their expression levels were more or less the 
same before and after siRNA transfection (Fig. 5.3.7). The results suggested that 
PMS2 may act as a direct signaling molecule in cisplatin-induced apoptosis. The 
proposed pathway of cisplatin-induced apoptosis was presented in Fig, 5.4.1. It was 
hypothesized that cisplatin mediated apoptosis through the extrinsic pathway by 
interacting with Fas, either by binding with Fas or transactivating the expression of 
Fas. This signaled the binding of F A D D to Fas receptor and subsequently combined 
with pro-caspase 8 to form a complex called DISC. DISC then transactivated pro-
caspase 8 to active caspase 8 which cleaved the executioner caspase, caspase 3, and 
apoptosis was initiated consequently. In the future, the promoter activity of Fas will 
be investigated by Luciferase Reporter Assay so as to further confirm the above 
hypothesis. 
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Fig. 5.4.1. The proposed pathway of cisplatin-induced apoptosis signaled by PMS2. 
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Chapter 6 
General Discussion and Conclusion 
In order to have a better treatment outcome for cancer, continuous work 
should be done to obtain a clear picture for the treatment resistance developed in 
cancer cells. It was found that the permanent change in the transcriptome was the 
main reason for the development of drug resistance in hypoxia/reoxygenation treated 
HepG2 and A431 carcinoma cells. 
6.1 Diverse sensitivity for hypoxia/reoxygenation treated cells to anticancer 
drugs 
The sensitivity to common clinically used cancer therapeutics was studied in HepG2 
and A431 cells. It consisted of platinum drugs, topoisomerase I or II inhibitors， 
antibiotic, cytokines, antifolate drug, mitotic inhibitors and oxidizing agent. In 
general, both HepG2 and A431 cells became more resistant to chemotherapy after 
hypoxia/reoxygenation treatment. In details, GIOHR and G20HR were more resistant 
to cisplatin, carboplatin, camptothecin, 10-hydroxy camptothecin and methotrexate 
while AlOHR and A20HR were more resistant to carboplatin, doxorubicin, hydrogen 
peroxide, IFNa and IFNy. The details for the resistance mechanisms of the above 
drugs were required to be further studied and that may hint for the direction of 
research discussed in Chapter 2.4. It was believed that the reasons for the resistance 
mechanisms were multifactorial. The therapeutic target was advised to be focused on 
the gene or pathway that had the greatest contribution for the resistance mechanism. 
In addition, it was observed that different cancer cell lines had diverse change in the 
sensitivity of drugs after hypoxia/reoxygenation treatment. 
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6.2 Resistance mechanism of doxorubicin in AlOHR and A20HR cells 
Among all the drugs examined, doxorubicin was one of the drugs that was chosen for 
an in-depth study. Although overexpression of mdrl was the most frequently 
mentioned reason for the doxorubicin resistance in cancer cells, no report illustrated 
the resistance mechanism of doxorubicin in cancer cells with hypoxia/reoxygenated 
treatment yet. W e found that the hypoxia/reoxygenation treated AlOHR and A20HR 
cells were more resistant to doxorubicin than the normoxic AP cells and the 
resistance was related to the overexpression of mdrl gene. It was believed that 
hypoxia/reoxygenation treatment changed the methylation status of the promoter 
region of mdrl gene in AlOHR and A20HR cells. The hypomethylated mdrl's 
promoter facilitated the transcription of mdrl m R N A and subsequently more P-
glycoprotein was translated. Then more doxorubicin molecules could be pumped out 
of the carcinoma cells and thus reduced the intracellular concentration of doxorubicin 
upon doxorubicin treatment. Thereby, more carcinoma cells survived and they 
became resistant to doxorubicin. 
6.3 Resistance mechanism of cisplatin in GIOHR and G20HR cells 
Another drug picked up for the in-depth study of its resistance mechanism in 
hypoxia/reoxygenation treated cells was cisplatin. Despite its long history of usage in 
cancer patients, extensive amount of reports about cisplatin resistance urged to study 
its resistance mechanism so as to find out a better treatment scheme. In the present 
study, hypoxia/reoxygenation treated GIOHR and G20HR cells were found to be 
more resistant to cisplatin than that of the normoxic GP cells. Further investigation 
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revealed that the cisplatin resistance was somehow related to the expression level of 
one particular mismatch repair gene, PMS2. Unlike the case in doxorubicin 
resistance, the expression level of PMS2 was significantly down-regulated after 
hypoxia/reoxygenation treatment. By the technique of RNAi interference, it was 
proven that reduced level of PMS2 conferred cisplatin resistance in HepG2 cells. 
Furthermore, hypoxia/reoxygenation was suspected to down-regulate the expression 
of PMS2 in HepG2 cells through epigenetic regulation such as D N A methylation and 
histone deacetylation. 
6.4 The role of PMS2 as a direct signaling molecule and the alteration of 
apoptotic proteins in cisplatin-induced apoptosis 
As a lot of drugs killed the cancer cells through particular events that 
eventually triggered apoptosis, it is therefore worth finding of any differences in the 
expressions of different apoptotic genes in hypoxia/reoxygenation treated cells which 
may alter the extent of apoptosis upon drug treatment. Beforehand, it was found that 
the sensitivity to cisplatin was directly correlated with the extent of apoptosis in 
which fewer GIOHR cells were found to undergo apoptosis compared with that of 
GP cells. Besides, the cisplatin-induced apoptosis was mediated by PMS2. From the 
basal expression profile of GP and GIOHR cells, it seemed that 
hypoxia/reoxygenation treatment rendered the HepG2 cells down-regulating the pro-
apoptotic proteins such as Fas, FADD, caspase 9 and caspase 3 but up-regulating the 
anti-apoptotic proteins such as Bcl-2. That may explain the resistant property of 
GIOHR cells towards drugs such as cisplatin. Moreover, PMS2 was suspected to act 
as a direct signaling molecule in mediating the cisplatin-induced apoptosis as the 
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knockdown of PMS2 altered the expression of apoptotic proteins in the intrinsic 
pathway. The finding is exciting because few of the mismatch repair gene was 
suggested to participate directly in the apoptotic pathway. 
6.5 Future work 
Tones of works remained to be done if we would like to have a clear picture 
about how hypoxia/reoxygenation may affect the drug response in cells. The 
resistance mechanisms of drugs other than doxorubicin and cisplatin in the 
hypoxia/reoxygenation treated carcinoma cells can be examined by RT-PCR, 
Western blotting and RNAi interference so as to find out the target gene(s).For 
example, the resistance mechanism of camptothecin in HepG2 cells may be due to 
the reduced expression of topoisomerase I while the resistance mechanism of IFNa 
may be due to the defect in Jak-Stat proteins. For the resistance mechanism of 
doxorubicin in AlOHR and A20HR cells, the role of histone deacetylation in the 
expression of mdrl could be investigated by the use of histone deacetylase inhibitor, 
trichostatin A. For the resistance mechanism of cisplatin in GIOHR and G20HR, 
methylation specific PCR and sequencing of the PMS2 promoter could be carried out 
in order to evaluate the methylation status of the PMS2 promoter and further 
confirmed the role of promoter methylation in the expression of mdrl and P-
glycoprotein. Last but not the least, the interaction between PMS2 and Fas could be 
determined by Luciferase Reporter Assay so that the role of PMS2 in triggering 
extrinsic apoptotic pathway could be proven. Hopefully, the present study can give 
some insight into the design of more appropriate treatment strategy for the cancer 
patients, especially for those bearing solid tumors. 
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